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A range of fluorescein derivatives were synthesised via Pd
0
-mediated cross-coupling 
chemistry of the mono triflate of fluorescein with a variety of boronic acids and the 
optical properties of each dye was studied. Among these derivatives, a new 
multicolour pH–dependant anthofluorescein which was highly sensitive to pH 
changes and viscosity changes was identified.  
 
Work was carried out to explore intracellular catalysis based on the 
immobilisation of Pd
0 
nanoparticles on microspheres. The entrapped Pd
0
 
nanoparticles were rapidly taken up by cells, stay harmlessly within the cytoplasm 
for days and were shown to carry out novel cell-based chemistry. This included an 
allylcarbamate cleavage and a Suzuki-Miyaura cross-coupling reaction for the in situ 
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CHAPTER 1:  
INTRODUCTION 
 
1.1 Palladium as a Catalyst 
Over recent years, palladium-catalysed coupling reactions have become a key 
method in organic synthesis, the so-called cross-coupling reaction becoming a very 
powerful method for the creation of new C-C bonds.
1, 2
 Pd-catalyzed cross-couplings 





 and molecules used in the electronics industry.
5
 For 
their work in demonstrating the versatility of the catalyst in synthetic chemistry, 
Richard F. Heck, Ei-ichi Negishi and Akira Suzuki were awarded the 2010 Nobel 
Prize in chemistry for the development of ‘’Palladium-catalyzed cross-couplings in 
organic synthesis’’.
5
   
 
1.2 Palladium and its Applications  
Palladium plays an important role in chemical transformations and is a catalyst in the 
synthesis of a range of molecules.
3, 4, 6
 Palladium is often mixed with other platinum 
group metals ruthenium, rhodium, osmium, iridium, and platinum and has strong 
catalytic activity for reactions such as hydrogenation, dehydrogenation, oxidation 
and hydrogenolysis. Palladium catalysts are used for example for the acetoxylation 
of ethylene to vinyl acetate and in the manufacture of sulfuric acid and methanol. 
Due to its lower cost, palladium is also used in telecommunication and electric 
equipment as Pd-based contact materials to replace gold.
7
 In addition, Pd has also 
been widely used to prepare dental filling materials and produce fine jewellery. For 
many years, automobiles have been equipped with Pd-based catalysts to minimise 
the emission of carbon monoxide, nitrogen oxides and hydrocarbons from fuel 
combustion.
8
 In biomedical applications, Pd-103 is widely used in permanent low 
dose radiation (LDR) brachytherapy as a prostate cancer treatment. Palladium emits 




Meanwhile, Pd(II) complexes  are able to intercalate in the double helix of DNA and 




1.3 Problems with Palladium Catalysts 
There is no longer doubt that the development of sustainable chemistry will motivate 
the emergence of efficient processes to solve current environmental issues for 
generations to come.
12
 Limitation of natural resources, reduction of wastes, 
maximising renewability, and development of environmentally benign reagents are 
the next challenges for the chemical sciences. Therefore, environmentally benign 
processes for the recovery of Pd are of high interest.  
 
Recovery of waste Pd is therefore of prime importance. It is generally pointed 
out that heterogeneous Pd systems have a catalytic activity lower than the 
homogeneous form while Pd often leaches out from the heterogeneous support 
contaminating the product and complicating recycling.
13-15
 In addition, its use is 
often complicated by issues surrounding the separation of the palladium and ligands 
from the desired product while recovery and recycling becomes a major practical and 
economic issue with respect to large-scale applications.
16
 Current techniques include 
costly and non-ecologically friendly processes, such as pyrometallurgy (processes 
used in the separation and concentration to enable recovery of valuable metals), 




1.4 Solving the Problem  
Many studies have been performed aimed at improving the drawbacks previously 
described. One promising solution to this problem is the immobilisation of Pd on a 
solid support.
16, 18
 In recent years there have been growing efforts in the area of Pd 
immobilisation, focusing on the development of insoluble supports to address the 
concerns of catalyst recovery and reusability. 
 3 
1.4.1 General Methods  
Over the past few years, a number of groups have immobilized a variety of Pd 
catalysts onto a range of other insoluble supports, most notably polymers. The most 
generally utilized methods for immobilization are physical adsorption of Pd 
nanoparticles (PdNPs) onto a solid support. Pd nanoparticles supported on insoluble 
solids are materials of considerable current interest in fundamental scientific fields as 
well as in environment-friendly recyclable catalytic applications.
19, 20
 Advantages of 
PdNPs, includes the versatility of Pd as a catalyst and the extremely large surface-to-
volume ratio.
2, 21-23



















1.4.2 Modern Methods  
Kobayashi demonstrated a technique for immobilising catalysts into polymers in 
order to address recovery and recycling issues. This was based on physical 
envelopment by the polymers and also on electronic interactions between the 
electrons of the aryl rings of polystyrene-based polymers and vacant orbitals onto the 
catalysts. For example, he developed polymer-supported catalysts such as 





 This method was successfully applied to 
immobilising palladium catalysts which were used for allylic substitution and Suzuki 
cross-coupling reactions.
33
 Another success was heterogeneous palladium catalyst 
generated using polymer incarceration methods based on microencapsulation and 
cross-linking. The Pd catalyst showed high activity in hydrogenation, 
carbon−carbon, and carbon−oxygen bond-forming reactions as well as good recovery 
and reuse.
33, 34 Most recently, this technique was used to developed a polymer-
incarcerated bimetallic (Au-Pd) nanoclusters as a catalyst for the sequential 





Another method was reported by Ley in 2002.
36
 Polyurea was believed to be 
a appropriate encapsulation matrix because of the capability of the urea functionality 
to ligate and retain metal species such as Pd(OAc)2. An interfacial polymerisation 
approach was used to encapsulate Pd(OAc)2 and PdNPs in polyurea microcapsules 







  In addition, osmium tetroxide has been microencapsulated in a 
polyurea matrix through an in situ interfacial polymerization approach. This has been 
used as a catalyst in the dihydroxylation of olefins as well as excellent activity when 




Meanwhile, Bradley demonstrated that palladium particles could be 
permanently immobilised in PS-PEG resins
16,18
 using an amide molecular ‘band’, 
which minimises palladium particle leaching. These supported catalysts were used to 
perform Suzuki–Miyaura, Sonogashira–Hagihara and Heck–Mizoroki cross-coupling 
reactions and were heterogeneous in nature and the materials could be recycled 
without loss of activity. In this technique, palladium acetate (Pd(OAc)2) was used as 
a precursor to the Pd
0
 catalyst. Soluble Pd(OAc)2 was adsorbed  by the support. The 
cross-linked captured palladium (XLPd) was prepared by treating a mixture of solid 
support with Pd(OAc)2 in toluene at 80 °C for 10 min and then room temperature for 
2 hours to afford brown colored resin-captured. The resin was filtered and then 
treated with 10% hydrazine hydrate in methanol to give a black resin due to the 
trapped Pd
0
 nanoparticles. Subsequently, the amino groups on the supports were 
“fixed and tangled” by cross-linking ensuring permanent capture of the PdNPs on the 

















i.  80°C, 10 min
















Figure 1.1 Preparation of entrapped and entanglement Pd
0
 nanoparticles. (A) 









1.5 Catalysts: A Brief Clasification 
For many years, catalysts have played very important roles to make our lives easier. 
Catalysts must be able to increase reaction rates by reducing the activation energy 
and satisfy three criteria; Firstly, the chemical composition of the catalytic agents 
need to be unchanged upon completion of the reaction, secondly, minimal amounts 
of catalyst should be enough for the transformation of the reacting substances of 




There are 2 distinct group of catalyst, homogeneous and heterogeneous 
(Figure 1.2).
41
 In heterogeneous catalysis the reactants and the catalyst are in 
different phases, while homogeneous catalysis the reactants and the catalyst are in 
same phase.  
 
Enzymes are the representative biocatalysts known to catalyse metabolic 
reactions in living organisms. The main benefits offered by enzymes are their highl 
activities (10–10,000 s
-1
) compared with chemocatalysts (1–10 s
-1
), selectivity and 
 6 
greenness as well as lack of cytotoxicity.
42
 Chemocatalysts also can be divided into 
three categories, inorganic, organometallic and organocatalysts. Generally, 
heterogeneous catalysts are inorganic solids such as metals, metal oxides and metal 
sulfides, whereas organometallic compounds are widely used in homogeneous 
catalysis. Organocatalysis includes all metal-free organic catalysts of both low and 
high molecular weight but are inefficient compared to the enzyme systems.
43
 
Interestingly, chemocatalysts are becoming more biocompatible by mimicking 
biocatalysts both in size and mechanism. For example, Brunner synthesised 
organometallic catalysts that were enlarged by anchoring to dendrimers 
(dendrizymes)
44









1.6 Transition Metals in Chemical Biology 
Transition metals have been used in biological systems because of their remarkable 
catalytic activity. Cells acquire a range of transition metals (sometime referred as 
trace elements) and frequently utilize them in proteins, where they can carry out 
catalytic activity. These are often required cofactors in biological systems, but due to 
the reactivity they can also be cytotoxic reactions even at low concentrations.
46, 47
 




Transition metals ions such as zinc, copper, iron are essential for many 
biological processes.
49, 50












human body (2-3g) with its highest concentrations occuring in the brain. Zinc is 
required in numerous metallo-enzymes which are involved in metabolism, maintain 
the immune system that protects the body against disease, as well as to support 
normal growth and development during pregnancy, childhood, and adolescence.
50, 51
 
Other transition metal such as iron and copper, which can exist in multiple oxidation 
states are very important for the cascades of electron transfer reactions that are 
characteristic of cellular processes. In fact, it is the answer to oxygen transportation, 
photosynthesis, nitrogen fixation, and respiration in most organisms.
46, 51-53
 Small 
alterations in iron concentration have been implicated in many diseases including 




However, much still remains to be revealed about the importance of metal 
ions in biological systems.
49
 Recently, developments in small-molecule fluorescent 
probes for metal ions detection in living cells have been reported in order to 











1.7 Fluorescence: A Brief History 
The first fluorescent molecule reported was the natural product quinine, an important 
chemical for medical and organic chemistry (Figure 1.3).
56
 Stokes explained how 
quinine was capable of absorbing energy from external sources and then emitting the 






Figure 1.3 Structure of quinine. 
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The well-known xanthene dye fluorescein (1) was first reported by Baeyer in 
1871, and its remains one of the most broadly utilized probes in modern biochemical, 
biological, and medicinal research.
58, 59
 It was prepared from phthalic anhydride and 
resorcinol in the presence of zinc chloride via a Friedel-Crafts reaction  (Scheme 1.1).  
 
Scheme 1.1 The preparation of fluorescein (1) by the condensation of resorcinol with 
phthalic anhydride catalyzed with zinc chloride. 
 
1.8  Fluorescence  
The fluorescence phenomenon was first described in 1852.
57
 Fluorescent molecules 
can be excited, by absorption of light and electron excitation to a higher energy state 
(excited state) (Figure 1.4). The energy of the excited state, which cannot be 
maintained for long, subsequently “decays” or decreases resulting in the emission of 
light energy. This process is called fluorescence.  
 
 
Figure 1.4 Fluorophore molecules capable to absorb and emit energy as visible 
light. 
 
A fluorophore is a molecule that is able to fluorescence. This process can be 
explained by the Jablonski diagram in Figure 1.5. In its ground state level, the 
fluorophore molecules are in a low-energy, stable configuration. When a fluorophore 
 9 
absorbs light energy, it is usually excited to a higher vibrational energy level in the 
highest excited state (1).  At this point, the fluorophore is now in an unstable state 
(high energy), rapidly relaxing to the lowest energy level (lowest excited state) which 
is semi-stable state (2). Transition from the upper to lower excited state is termed 
vibrational relaxation and occurs in about a picosecond or less. Next, the fluorophore 
molecule rearranges from the lowest-excited state back to the ground state (more 
stable), consequently the excess energy is released and emitted as light (3). The 
emitted light has lower energy (longer wavelength) compared with the energy 
absorbed. The fluorophore which was in a ground state can absorb light energy again 
and go through the entire process repeatedly.              
 
Figure 1.5 The Jablonski diagram:  (1) Excitation of a fluorophore through the 
absorption of light.  (2) A short-lived excited lifetime undergoes vibrational energy 
loss with a little loss of energy. (3) The fluorophore reverts back to its ground state, 
and emits visible light. The light emitted is always of a longer wavelength (low 
energy) than the light energy absorbed, because energy is lost in the transient 
excited state lifetime in Step (2).                                    
 
Nowadays, fluorescence is used by many scientists in many disciplines. In 
fact, modern fluorescence is now a dominant methodology used in biotechnology, 
medical diagnostics, DNA sequencing, forensics, and genetic analysis.
60
 Some dyes 
which are commercially used are shown in Figure 1.6.   
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Figure 1.6 Examples of some widely used fluorescent dyes (A) ethidium bromide, (B) 
Alexa Fluor dyes, (C) fluorescein and (D) BODIPY. 
 
1.9  Fluorescence and a few Applications  
Fluorescence is powerful method currently available for observation of dynamic 
intracellular processes in living cells.
61
 This methods allows high sensitivity and 




Fluorescence-based methods also include assays for biomolecules, metabolic 
enzymes, DNA sequencing, research into biomolecule dynamics, cell signalling and 
adaptation, and fluorescence in situ hybridisation to identify specific DNA and/or 
RNA sequences in tissues.
63, 64
 Green fluorescent protein (GFP) is the most popular 
tagging agent for cellular imaging.
64-66
 GFP was first isolated from the jellyfish 
Aequorea victoria and widely used as a reporter for gene expression and as a marker 
for biomolecules.
62, 64, 65, 67, 68
 GFP is genetically encoded and requires no cofactors, 
and can be applied to analyze protein expression and localization in living systems. 
In addition, one advantage of fluorescent proteins is that they can be targeted to 
specific organelles such as the cytosol, nucleus, mitochondria, trans-Golgi, and 
 11 
endoplasmic reticulum by expressing them in conjugation with appropriate targeting 
peptides or proteins.
69
 Disadvantages of using GFP are that it requires significant 
amounts of work to express these proteins and the range of fluorescence wavelengths 
available is limited.
70
 In the case of GFP, these relatively large proteins can perturb 
the protein structure and may influence the expression, localization or function of the 
protein to which they are attached. 
 
1.9.1  Advantages 
Over the years, fluorescein along with microscopy instrumentation has frequently 
been used in cell biology to measure important biochemical species or monitor 
biochemical pathways in living cells, tissues  and organisms.
67, 71
 A wide variety of 
fluorescein derivatives have been prepared and used as fluorescent derivatisation 
reagents. For example (Figure 1.7), 5(6)-carboxyfluorescein (B), 5(6)-
carboxyfluorescein succinimidyl ester (C), 5-iodoacetamidofluorescein (D), and 
fluorescein isothiocyanate (E), which make them particularly suitable for biological 
evaluation in which fluorescein is covalently attached to molecules such as peptides, 











1.9.2 Challenges with Fluorescein 
The application of fluorescence techniques to living specimens presents many 
challenges. For example, the fluorescence of fluorescein is pH dependant (between 5 
and 8.5), and its maximum intensity occurs at a pH > 8.5.  Moreover, many 
fluorescein conjugates are unstable with respect to the illumination produced in most 
fluorescence instrumentation.
72
 The result is irreversible photobleaching, which 
typically results in a rapid decrease in the fluorescence. In aqueous solution (Figure 
1.8) it can exist in cationic (I), neutral (A), anionic (J), and dianionic (K) forms, 
making its absorption and fluorescence properties strongly pH dependent. The pKa 
of fluorescein (A) in water is approximately 6.4; at the physiological pH range a 
considerable population of fluorescein is in the protonated, nonfluorescent form L 








































1.10   Aim of the Thesis 
The goal of this thesis was to explore the use of Pd(0) catalysis in the generation of 
fluorophores. This included using Pd
0
 to perform intracellular catalysis. 
Heterogeneous catalysts were chosen due to their stability and non-toxic nature. Pd
0
-
mediated intracellular chemistry was initiated with deprotection chemistry before 
moving to a challenging reaction, the formation of a C-C bond. This also involved 
the design of a new switch-on profile fluorophore used for quantification of catalytic 
activity. This effort initiates a new approach to the use of transition-metal catalysis as 
a tool for biological chemistry. 
 
Another objective was to use Pd(0) catalysis to functionalise fluorescein by 
Suzuki cross-coupling in order to enhance its optical properties. A library of 
fluorescein analogues was generated and studied. Among these derivatives, it was 




















BREAKING OUT FROM THE 
FLUORESCEIN STRUCTURE 
 
This chapter is divided into two sub-chapters: 
 
A. A fluorescein-inspired Anthocyanidin pH Sensor73 
 
B. Synthesis of Novel Anthofluorescein Derivatives: 
Study of the Influence of Conjugation Expanders on 
the Fluorescent Properties 
  
2.1 Background and Significance 
Fluorescent moieties are of tremendous value as probes in cell biology due to their 
fast-  response, high sensitivity, and the ability to afford good spatial resolution 
through microscopic imaging.
61
 Fluorescein is one of the most commonly used labels 
in biological assays because of its ready availability, solubility in aqueous buffers, 
high fluorescence quantum yield, stability and because variants, such as 
carboxyfluorescein allow ease of conjugation of target molecules.
59, 61
 Additionally 




Many of the typical cellular fluorescent probes for pH measurements are 
based on fluorescein and its derivatives since fluorescein exhibits multiple pH-
dependent equilibria. Many fluorescein-based pH probes have been generated 
including fluorescein-derivatised polythiophene, fluorescein sulfonic acids and 
seminaphthofluorescein derivatives.    
 
Significantly, fluorescein remains one of the most broadly utilized 
fluorophores in modern biochemical, biological, and medicinal research. Due to the 
particular needs of each and every study, fluorescent dyes and probes with a myriad 
of defined optical, chemical, and biological properties are in high demand. In order 
to fulfil the needs in biology, chemistry and materials science, scientists have 
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recently created numerous fluorescent probes and sensors for in vitro and in vivo 
studies such as imaging in cell biology,
67
 including sensors for studying intracellular 
pH,
70
 fluorescent sensors for study intracellular viscosity
74
 and fluorescent sensors 




2.2 pH Sensors 
Great effort has been focused on the development of fluorescent pH chemosensors.
76-
80
 Hence, specific attention has been paid to  the synthesis of highly sensitive 
indicators within the physiological pH range.
81, 82
 In this area fluorescein and its 
derivatives are perhaps the most widely used fluorescent pH probes due in part to 




2.2.1  Intracellular pH  
Cells need to maintain their physiological pH in a controlled manner in order to 
continue viable cellular functions.
70





 plays very important roles in cellular, 







 and muscle contraction.
93
 Monitoring pH changes inside living cells is 
important for investigating cellular internalization pathways, such as phagocytosis 
and endocytosis.
94
 Abnormal pH is often associated with cellular dysfunction and is 




 However our 
understanding of how these changes affects physiological systems is limited. To 





2.2.2 Fluorescent pH Indicators 
Compared to other methods such as absorbance spectroscopy, microelectrodes and 
NMR, fluorescence cellular analysis has many positive attributes in allowing the 
measurement of cellular pH changes. Moreover, it has high sensitivity, while the 
probes are easy to handle and  importantly are non-cytotoxic.
70
 Measurements of pH 
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qualitatively can be attained by using fluorescent probes that switch on or off at 
spectra pH ranges. However, such measurements can be influenced by numerous 
factors, including temperature and even excitation intensities. This problem can be 
resolved by the use of “ratiometric analysis”, a method that uses fluorescent sensors 




The main benefit when using ratiometric methods is accuracy because they 
are not influenced by parameters such as local probe concentration, optical path 





2.2.3 Fluorescein-Based pH Sensors 
Tsien first introduced 2,7-bis-(2-carboxyethyl)-5-(and-6-)carboxyfluorescein 
(known as BCECF) which is the most widely used pH indicator for measuring 





Figure 2.1 BCECF, Φ=0.84 (0.1 M NaOH), λmax abs 503nm, λmax em 525nm. 
 







 such as the endoplasmic reticulum.
101
 Like fluorescein, 
carboxyfluorescein, and fluorescein sulfonic acid, the absorbance of BCECF is 





A homolog of BCECF named 2,7-bis-(2-carboxypropyl)-5-(and-6-)-
carboxyfluorescein (BCPCF) has been synthesised (Figure 2.2) which has 2-
 18 
carboxypropyl substituents at the 2- and 7-xanthene positions.  BCPCF has better 





Figure 2.2 BCPCF, Φ=0.83 (0.1 M NaOH), λmax abs 505nm, λmax em 527nm. 
 
Although BCECF and BCPCF are favoured for intracellular pH 
measurements, fluorescein sulfonic acid, and particularly carboxyfluorescein (Figure 
2.3) are still widely used for pH studies because they are inexpensive to synthesise 
on a large scale.
107
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Figure 2.3 Structure of fluorescein derivatives such as fluorescein sulfonic acid and 




Another probe used for measuring pH values is fluorescein diacetate (Figure 
2.4). This liberates fluorescein via cellular hydrolysis but since it leaches out from 
 19 
the cells, it is difficult to determine if fluorescence intensity decreases are due to 





Figure 2.4 Structure of fluorescein diacetate. 
 
To address the leaking problem the more highly charged derivatives, 5- and 
6-carboxyfluorescein are preferred (Figure 2.5).  
 
 
Figure 2.5 Structure of 5-carboxyfluorescein diacetate. 
 
The 5- and 6-sulfofluoresceins (Figure 2.3) are even more water-soluble and 
even better retained inside cells compared with carboxyfluorescein. Unfortunately, 
these sulfonic acid derivatives are not favourable as intracellular pH indicators since 
their diacetate forms hardly diffuse into cells.
100
 Some other fluorescein derivatives 
such as dimethylcarboxyfluorescein can be used as intracellular pH indicators, but 




2.3 Viscosity Sensors 
2.3.1  Conventional Viscometer  
Viscosity is usually measured on a large volume of a fluid. The most typical 
instruments are a falling- ball viscometer but cone-and-plate viscometers are also 





2.3.2  Fluorescent Viscosity Sensors 
In order to study intracellular viscosity, accurate measurements of viscosity and in 
particular real-time measurements of viscosity changes on a microscopic scale 
require of the development of methods that are appropriate at the molecular level.
111 
This has been accomplished through the use of molecular rotors. Molecular 
rotors are a group of fluorescent molecules that were characterized in the 1970s to 
1980s.
112
 Their most important property is that the molecule has two modes of 
relaxation either by photon emission (fluorescence) or by intermolecular rotation 
which will decrease fluorescent intensity due to the loss of energy. The rotation can 
be reduced if the molecule is in a highly viscous solvent. Consequently, the quantum 
yield and fluorescent intensity of the fluorophore is related to the viscosity of the 
fluid. Haidekker has shown that increased viscosity leads to increased quantum yield 




For many years molecular rotors have been successfully used as viscosity 




 and also as probes 
for cell membranes.
116
 Molecular rotors have been used in cell mechanotransduction 
research for observing changes in the fluidity of the cell membrane and shown good 
potential as fluorescent probes in biological studies.
113
   
 
2.4 Molecular Strategies of Modifying Fluorescence 
The fluorescein structure can be divided into two parts, the benzene and the xanthene 
moiety (Figure 2.6). In 2005 Urano reported that the carboxylic group actually is not 
important for the fluorescent properties of fluorescein, its just keeps the benzene and 
xanthane moieties orthogonal to each other
117
 because there are no groundstate 
interaction between these moieties.  In other words, modification of the benzene 
moiety will not be able to enhance the optical properties of fluorescein.  Thus 











Figure 2.6 The fluorescein structure divided into two parts, the aryl moiety and the 
fluorophore. 
 
Modification strategies have comprised extension of double-bond conjugation 
and decoration with additional rings, electron donating/withdrawing or charged 
substituents such as sulfonates.
118, 119
 A range of fluorescein derivatives have been 





 substituents to shift the phenolic pKa to a lower value.
123
 
On the other hand, installation of an electron-donating group such as an alkyl group 
ortho to the phenol groups increases their pKa. Acylation or alkylation of the 
phenolic groups of fluorescence forces this platform to adopt a closed, colorless and 
nonfluorecent lactone ring and serves as the basis for a variety of fluorogenic 
substrates for phosphatases, glycosylases, esterases, and other enzymes.
124, 125
 For 
example, 3,6-fluorescein diphosphate (FDP) has been widely used for monitoring 
phosphatase (PTPase) activity (Scheme 2.1), the hydrolysis of the two phosphate by 























2.5 Aim of the Research  
Encouraged by the vast opportunities and demand for fluorescein-based sensors, 
research was carried out to synthesize a range of fluorescein derivatives. The 
modifications were designed to utilize palladium catalysis with Suzuki cross-
coupling chemistry. Fluorescein derivatives were screened, characterized and their 
spectroscopic properties studied. This straightforward modification via a simple 
reaction would contribute to a flexible method for fluorescence probe synthesis.  
 
2.6 A fluorescein- inspired Anthocyanidin- pH Sensor73 
  
2.6.1 Introduction 
Anthocyanidins are the chromophores of a well-known family of natural dyes and 
are characterized by their broad spectral window, which is controlled by the various 
substituents on the benzopyrylium core and pH.
127
 Inspired by the general structures 
of the anthocyanidins (Figure 2.7), work focused on the modification of fluorescein 






















Figure 2.7 General structures of anthocyanidins. 
 
This simple modification consisted of two reactions, triflation and Suzuki cross-
coupling. The first step introduced the triflate group via microwave-assisted mono-
triflation (2) of fluorescein (1) using one equivalent of 
phenylbis(trifluoromethanesulfonimide)
128
 (a mild triflation reagent) (Scheme 2.2). 
This triflate protected fluorescein had reduced fluorescent properties (background) 









The second step was a Suzuki reaction between the fluorescein mono-triflate 
(2) and a boronic acid. The palladium-catalyzed cross-coupling of aryl halides (or 
triflates) with boronic acids is one of the most versatile and commonly utilized 
reactions for the construction of carbon-carbon bonds, in particular for the formation 
of biaryls.
129, 130
 In this case, p-hydroxyphenylboronic acid was selected to be 
coupled with fluorescein mono-triflate (2). Suzuki aryl palladium-catalyzed cross-
coupling of fluorescein mono-triflate with p-hydroxyphenylboronic acid give the 
fluorescein derivative (Scheme 2.3). The product, named anthofluorescein (3) was 
expected to have an extra electron conjugation due to the additional aryl ring.  
  
Heterogeneous catalysis using polystyrene resin captured palladium (XL-RC 
Pd)
16
 or palladium acetate (Pd(OAc)2) were used for this reaction and gave yields of 




Scheme 2.3 Suzuki cross-coupling between fluorescein mono-triflate, 2, and p-







2.6.2    Optical Properties of Anthofluorescein (3) 
2.6.2.1   pH dependence  
The solution of 50 µM anthofluorescein was placed in different buffers (pH 1-13). 
This simple experiment clearly shows that anthofluorescein has distinct optical 
properties from pH 7 to pH 13 turning from yellow to red (Figure 2.8).  
 
 
Figure 2.8 50µM solutions of anthofluorescein in a set of pH buffers ranged from 1 
to 13. 
 
2.6.2.2   Absorptivity study 
A study of the absorptivity and the fluorescent properties of the novel dye confirmed 
that the optical properties of anthofluorescein were quite different from those of 
fluorescein, with both the absorption and emission spectra highly influenced by pH 
(as is also observed for the anthocyanidins). Spectrophotometric analysis of 
anthofluorescein solutions (50 µM) at distinct pH values  showed that absorbance 
increased with pH, with the largest impact being observed between pH 7 and 10 







Figure 2.9 (A) Absorption spectra of 50 µM solutions of anthofluorescein at pH 6–
13. (B) Images of the dye solutions at various pH values and its emission.  
 
 
Absorptivity greatly decayed at pH 13, indicating a large change in the 
composition of the aromatic forms. The changes seen in the fluorescence emission 
spectra between pH 7 and pH 13 most probably being due to the prototropic 






Figure 2.10 Emission spectra of anthofluorescein, with excitation at 450 nm: (A) pH 
6–9 and (B) pH 9–13. 
 
2.6.2.3   Excitation/emission analysis 
At pH 6 the dominant band in the emission spectrum occurred at 535nm. A shoulder 
at 570nm appears on this band at pH 7 and pH 8, which at pH 9 becomes the 
dominant band. Above pH 9 a blue shifted shoulder, at 510nm, begins to appear until 
at pH 13 the emission spectrum becomes identical to that of fluorescein (Figure 
2.11). The normalised emission spectra show clearly how the composition of the 






Figure 2.11 Excitation spectra, on the left, recorded at an emission wavelength of 
550nm, and emission spectra, on the right hand side, recorded at an excitation 
wavelength of 450nm, of anthofluorescein at pH 13 (grey), pH 12 (light blue), pH 11 
(dark blue), pH 10 (light green), pH 9 (dark green), pH 8 (pink), pH 7 (purple), and 






Figure 2.12 Normalised emission spectra (with an excitation wavelength of 450nm) 
of anthofluorescein at pH 13 (grey), pH 12 (light blue), pH 11 (dark blue), pH 10 





2.6.2.4   Quantum yield study 
The experimental quantum yield
132
 of anthofluorescein at pH 8, where maximal 
emission was observed, was very low (0.02), which in practice would limit 
applicability for cell assays. However, further analysis indicated that the quantum 
yield was highly influenced by the viscosity of the solution, with the quantum yield 
rising to 0.3 at pH 8 in 20% glycerol (viscosity cells cytoplasma),
133
 presumably due 
to a decrease in the rate of internal conversion mediated by the p-hydroxyphenyl 
group torsional motion.
134
 It would be expected that the changes in emission intensity 
and quantum yield would be mirrored by changes in fluorescence lifetime and, as 
such, the molecule could find application as a, potentially, very sensitive probe of 
local temperature and viscosity in fluorescence lifetime imaging microscopy.  
 
2.6.3  Cell Labelling/Viability Assay 
The classic example of pro-drugging dyes is the application of nonfluorescent 
acetoxylmethyl (AM) or acetate esters.  
 
A non-fluorescent derivative of anthofluorescein, 3´-acetyloxy-6´-(p-
acetyloxyphenyl)fluoran, 4, (AM anthofluorescein) was synthesized (Scheme 2.4) in 
order to enhance the cellular penetrability of anthofluorescein and also to eliminate 
extracellular background.  
 
 
Scheme 2.4 Synthesis of nonfluorescent bis-acetoxylmethyl of anthofluorescein (4). 
 
Acetoxymethyl anthofluorescein was incubated with HeLa cells for 2 h and 
then imaged using a 488/20 excitation filter. As expected, intracellular deacetylation 
led to the formation of anthofluorescein, which was identified by bright fluorescent 
yellow cells (Figure 2.13). Due to the higher viscosity of the cell cytoplasm 
 29 
(expected to be more akin to glycerol than water)
133
 the anthofluorescein dye was 
strongly emissive within the cells, confirming the previous viscosity observations. A 
diacetylated derivative of anthofluorescein 4 has been demonstrated to be cell 




Figure 2.13 HeLa cells were incubated for 2 h with a 25 µM solution of diacetylated 
anthofluorescein. Intracellular deacetylation to give anthofluorescein. Brightfield 
(left), Fluorescent image with 488nm excitation and no emission filter (right). 
 
2.6.4    Cytotoxicity of Anthofluorescein 
The fluorescent dyes can localize in any cellular compartment, and the fluorescent 
compounds may tend to accumulate in organelles having high concentrations of 
esterases. The acetoxylmethyl ester and liberated dye could also be cytotoxic. 
Cytotoxicity of the anthofluorescein was therefore tested on HeLa cell using an MTT 
assay (Figure 2.14). 
 
 
Figure 2.14 Cytotoxicity analysis of bis-acetoxylmethyl of anthofluorescein, 4 (25 
µM) on HeLa cells. 
 30 
The results suggested anthofluorescein was non-cytotoxic and did not perturb 
cell physiology after 8 hours. Based on microscopy analysis there was no significant 
leakage from cell (due to the presence of negative charges on the dye), therefore, 
anthofluorescein is a valuable candidate as a intracellular pH sensor.  
 
2.6.5 Advantages of Anthofluorescein Compared to the 
Traditional Fluoresceins 
Anthofluorescein is highly sensitive to pH changes between 7 and 10 and displays a 
green to red fluorescence shift in the physiological pH range, making it a candidate 
for biological studies. Its relatively cheap simple synthetic method makes the 
development of further multicolour fluorescence dyes from yellow to far-red 
practical. In addition, acetoxymethyl anthofluorescein has a low extracellular 
fluorescent background, giving excellent signal to noise ratios.  
 
2.6.6  Conclusion 
In conclusion a new pH-sensitive dye synthesized from fluorescein using a 
straightforward microwave-assisted two-step procedure consisting of mono-triflation 
and subsequent Suzuki aryl cross-coupling with p-hydroxyphenylboronic acid has 
been developed. The anthofluorescein was characterized by a highly pH sensitive 
absorption and fluorescence emission particularly in the pH range from 7 to 10 and 
good quantum yield in the physiological environment.  
A diacetylated derivative of anthofluorescein (4) successfully labelled living 
HeLa cells with no obvious cytotoxycity observed. This indicates that might become 
a tool for cell labelling and viability studies. The synthetic method provides a facile 
route to the development of new multicolor fluorescence dyes with red-shifted 




2.7 Synthesis of Novel Anthofluorescein Derivatives: The 
Influence of Conjugation Expanders on Fluorescent 
Properties 
 
2.7.1  Introduction 
Encouraged by the properties of anthofluorescein, research was focused on the 
modification of 2 using various boronic acids. A range of anthofluorescein 
derivatives were synthesised using different aryl and heteroaryl moieties decorated 
with electron donating/withdrawing groups as conjugation expanders.  
 
2.7.2  Synthesise of Anthofluorescein Derivatives 
The synthetic procedure of anthofluorescein derivative is outlined in Scheme 2.5. 
 
 
Scheme 2.5 Suzuki cross-coupling between compound fluorescein-monotriflate (2) 
and boronic acids (X). 
 
Suzuki cross-coupling between fluorescein-monotriflate (2) with heteroaryl 
and aryl boronic acids (X) and its biaryl compound (Y) are summarised in Table 2.1. 
 
2.7.2.1   Optical properties study 
The excitation and emission maximum (Ex/Em) of each derivative were recorded 
(Table 2.1). 
 
2.7.2.2   Quantum yield study 
The quantum yield measurement was made in ethanol at room temperature. The 




 Table 2.1 Heteroaryl boronic acid (entry 1-9) and aryl boronic acid (entry 10-22). 








5 78 480/532 0.51 
B 
 
6 73 480/536 0.50 
C 
 
7 75 482/528 0.49 
D 
 
8 70 480/531 0.47 
E 
 
9 78 480/537 0.56 
F 
 
10 63 482/533 0.45 
G 
 
11 88 477/528 0.46 
H 
 
12 80 480/536 0.42 
I 
 
13 78 479/538 0.40 
J 
 
14 68 470/535 0.30 
K 
 
15 63 477/525 0.32 
L 
 




17 83 470/532 0.23 
N 
 
18 78 478/533 0.22 
O 
 
19 85 480/532 0.29 
P 
 
20 80 480/530 0.29 
Q 
 
21 68 480/533 0.19 
R 
 
22 78 478/529 0.27 
S 
 
23 80 482/531 0.21 
T 
 
24 75 480/534 0.18 
U 
 
25 65 470/535 0.13 
V 
 





2.7.3 Further Investigation on 2-(3-(1-methyl-1H-indol-5-yl)-6-
oxo-6H-xanthen-9-yl) benzoate (9) 
Further investigation of 9 (Figure 2.15) which had highest quantum yield was 
carried out; specifically the behaviour of the optical properties in solvents of 












The study was on the behaviour of the dye in different viscosity solution and 
polarity of the solvent. The viscosity sensitivity of 9 was tested by measuring its 
fluorescent intensity in mixtures of ethylene glycol and glycerol. Mixtures of 
ethylene glycol and glycerol were prepared to afford solutions of different viscosity 
with a constant dye concentration.  
 
2.7.3.1   Effect of solvent viscosity on the fluorescent properties 
The relationship between viscosity η and quantum yield is shown by the Föster-
Hoffmann-equation
137
 (Equation 1), 
 
ηloglog xC +=Φ (1) 
 
Where C is a temperature-dependant constant and x is a dye dependant-constant. To 
illustrate this relationship, the emission spectra of 9 (5 µM) in a mixture of ethylene 
glycol and glycerol with different viscosities were determined (Table 2.1), 
(increasing glycerol content is known to increase viscosity with only minimal 
changes of solvent polarity).
111
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100:0 20:80 40:60 50:50 60:40 70:30 80:20 100: 0 
Viscosity 
(mPas) 
13.5 36 72 109 165 248 374 945 
 
Figure 2.16 shows the fluorescence intensity significantly increased with 
higher solvent viscosity. A higher glycerol content corresponds to a higher viscosity 
of the solvent which leads to increase emission intensity and suggested that 9 is 
strongly viscosity-dependant. A high viscosity environment means molecules 9 do 
not lose their energy via intermolecular rotation, therefore the energy was released by 


























Ethhylene glycol Gly/EthyGly (20:80) Gly/EthyGly (50:50)
Gly/EthyGly (80:20) Glycerol
 
Figure 2.16 Effect of solvent viscosity on the fluorescent intensity of 9 recorded with 
an excitation wavelength of 480nm. 
 
2.7.3.2   Effect of dye concentration on the fluorescent properties 
The emission intensity of 9 increased not only with increased of solvent viscosity but 
also with increased dye concentration. Figure 2.17 shows that the emission intensity 




Figure 2.17 Different concentration of 9 ranging from 2.5-10µM in glycerol/ethylene 
glycol (20:80), recorded with an excitation wavelength of 480nm. 
 
2.7.3.3   Effect of solvent viscosity and dye concentration  
The effects of solvent viscosity and dye concentration were further investigated. The 
experiment was carried out using four different concentrations of 9 (2.5, 5.0, 7.5 and 
10 µM) a five different viscosities (72, 109, 165, 248 and 374 mPas). The result 
shows linear relationship between fluorescent intensity versus viscosity of solvent 



































Figure 2.18 Effect of concentration 9 over viscosity of solvent, recorded with an 
excitation wavelength of 480nm. 
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2.7.3.4   Effect of solvent polarity on fluorescent intensity 
In this study, the influence of solvent polarity 9 was examined. The dielectric 
constant ∈ of the solvents was used as an index of its polarity.138 Four different 
solvents were used ethylene glycol, glycerol, DMSO, and benzene with dielectric 
constant values of 37.7, 42.5, 48.9 and 2.27 respectively. Figure 2.19 shows the 























Benzene Ethylene glycol Glycerol DMSO
 
Figure 2.19 Emission spectra of 9 (2.5µM) in selected solvents. Emission intensity 
increased in the moderately viscous ethylene glycol and in the highly viscous 
glycerol. The spectra recorded at excitation wavelength of 480nm.  
 
2.7.4    Cell Labelling/Viability Assay 
The cell viability assay of dye 9 was tested on HeLa cells by direct staining for 2 
hours. After the incubation time, the cells were washed, fixed using 4% 




Figure 2.20 HeLa cells were incubated with a 5 µM solution of 9 for 2 h (A) 




A series of anthofluorescein derivatives were synthesised via Suzuki cross-coupling 
and their spectroscopic properties studied. Emission spectra (Appendix I) showed all 
derivatives have a broad and slightly red-shift emission compared with fluorescein, 
due to the expanded electron conjugation on fluorophore skeleton. Among these 
derivatives, 9, which was synthesised by coupling between fluorescein-monotriflate 
and 1-methyl-1H-indole-5-boronic acid showed the fluorescent intensity was highly 
dependent on viscosity of the solvent. The fluorescent intensity was dramatically 
increased with the increase of viscosity ranges from 13.5 to 945 mPas. The effect of 
solvent polarity and concentration of dye on optical properties were further 
investigated. The results showed the emission intensity increased in the moderately 
viscous ethylene glycol and in the highly viscous glycerol as well as higher 
concentration of 9. Meanwhile, the cell viability assay test showed 9 was cell 
permeable and successfully labelled HeLa cells. These results strongly suggest 9 
behaves as a molecular rotor where its emission intensity depends on both viscosity 
and polarity of the solvents.  It is believed that compound 9 can be used as a micro-







WITH UNNATURAL METALS 
  
 
3.1 Background and Significance139 
Cellular biochemistry is governed by a wide range of enzymatic entities, with the 
complex cellular machinery engineered to perform numerous diverse chemical 
reactions.
140, 141
 Many of these reactions are catalyzed by transition metals, typically 
in the form of metalloproteins,
142 
which modulate a variety of transformations, 
ranging from highly selective oxidations to the efficient formation, lysis or 
isomerisation of multifarious chemical bonds.
140, 141
 Many groups have exploited the 
singular properties of these proteins with the generation of bio-inspired devices, 




Much of our understanding of reactions in living cells has been drawn from 
established biochemistry.
144
 Although many well-known in vitro assays are 
extremely effective, it is known that the setting of the cell is completely different 
from a test tube in a number of ways: (i) Many mRNA molecules, DNA and 
enzymes exist in low numbers and participate in random reaction events in the cell 
that are hidden in test tubes with large numbers of molecules. (ii) Reactions are 
regularly at nonequilibrium steady state in the cell. (iii) Many reactions are coupled 
in the cell, resulting in networks of complex interactions. (iv) Many proteins are in 
complex equilibria with each other. Consequently, a biochemical reaction in a single 





A growing area of reaction methodology is focused on the development of 
chemical transformations with the selectivity, kinetics and biocompatibility required 
to proceed in living systems with minimal interference with the cell. As such, some 
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metal-catalized reactions have been attempted inside living cell such as copper-
mediated click chemistry.
146, 147
 Unfortunately, this reaction is not, at the moment, 
compatible with living systems due to the strict requirement for copper, a metal that 
is toxic to cells and organisms.
148, 149
 In recent years, chemists and biologists have 
begun to share a common interest developing techniques to study biomolecules in 
their physiological environment. They have begun to shift away from the artificial 
confines of test tubes to investigate biological processes in the context of living cells 
and whole organisms.
64, 144
 This requires the challenging process of designing 
biocompatible catalysts and reagent/s which work under physiological conditions.
64, 
150
 In this context both advances in instrumentation and also the design of new 
fluorophores are very important.
151
 As such bioorganometallic chemistry has evolved 
as a fascinating field, full of possibilities and creative applications, ranging from 
highly-selective chemistries to the manipulation and in situ interrogation of a myriad 
of biological processes.
152
     
 
3.2  Chemical Reactions in Cells 
Among the numerous synthetic methods that chemists have developed, only a small 
number of them can be carried out under physiological conditions. The ability to 
carry out selective transformations inside a cell would allow researchers to 
manipulate or interrogate innumerable biological processes. For example, such 
catalysts could eventually be used to amplify signals by turning over a substrate 
multiple times,
150
 catalytically labelling or deactivating target biomolecules, 
activation of prodrugs and also intracellular synthesis of impermeable drug.
139
 
Biomolecules within cells could be covalently labelled with probes using 
bioorthogonal reactions. Fast chemical methods have been elegantly developed to 
detect DNA biosynthesis during cell proliferation via Click chemistry which does not 
require sample fixation or DNA denaturation and permits good structural 
preservation.
147
 Recently, Rao elegantly presented an approach for the constructing 
of large molecules within living cells via condensation reaction between 1,2-
aminothiol and 2-cyanobenzothiazole that occurs in vitro and in living cells.
153
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3.3 Challenges in Developing Artificial Intracellular 
Catalysts 
Nature has evolved to create extremely selective enzymes that allow for substrate 
recognition and subsequent reaction of functional groups with high efficiency and 
specificity. While this patient process has worked amazingly for nature, it is almost 
impossible for scientists to design and make new enzymatic entities to facilitate new 
selective covalent reactions such as the tagging of particular biomolecules.
64
 
Designing unnatural catalysts which work under physiological conditions, while very 
challenging due to their inherent toxicity,
154, 155
 offers an ideal alternative to this 
purpose.  
  
 The mode of action of any unnatural metal, and palladium in particular, in 
biological systems remains unclear. Due to their ability to form strong complexes 
with both inorganic and organic ligands, they have the potential not only to disturb 
cellular equilibria or replace other essential ions but also to interact with functional 
groups of macromolecules, thereby disturbing a variety of cellular processes.
156-158
 
Its ability to cross-link DNA inside the nucleus is probably the most important 
drawback of using metals of the platinum group such as palladium inside cells. 
 
In addition, intracellular catalysis must first take away any reaction that is 
sensitive to water. Designing metal-based catalysts which work under physiological 
conditions means the biocompatibility of the catalysts is crucial as it must have 
minimal or no reaction with biomolecules. The reaction desired should proceed with 
reasonable rate even when the concentration of the reactants are low. Most 
importantly, the reaction should only proceed inside the cells or even only at specific 
locations within the cells. All reagents used have to be cell-permeable and be 
retained within the cell while reaction products need to stay too to perform their 
function. Considering the abundant supply of thiols and amines in the cell, all 
reagents that are prone to nucleophilic attack might also need to be ruled out. 
Reactions that are sensitive to redox chemistry might be ineffective too due to the 
environment in the cell. Any reaction requiring heat (above 37 °C), high pressure, or 
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high concentrations to work will not be applicable. In addition, it needs to be 
considered that some reagent functionalities can be metabolized by cellular enzymes 
(e.g., esterases, phosphatases, sulfatases, proteases, etc.). Last but not least, toxicity 
and localization of reagent, product and by-product are one of the main challenges 
for metal-based intracellular catalysis. 
 
3.4  The Important Benefits of the Research 
For many years now, palladium has been among the most popular transition metals 
in modern organic/industrial synthesis and is widely used for a significant number of 
synthetic transformations.
2, 140
 However, the exceptional ability of palladium to 
catalyze a wide variety of chemical transformations has not yet been exploited in 




 Based on these facts and the massive opportunities palladium could offer in a 
living context, the presented research focuses on designing unique biocompatible 
heterogeneous catalyst based on the idea of immobilising palladium nanoparticles 
onto microspheres that “travel and stay” in the cytoplasm of cells.
16
 Such a truly 
heterogeneous catalyst would allow palladium chemistry to be performed within 
cells such as allylcarbamate cleavage and Suzuki-Miyaura chemistry. 
 
3.5   Designing a Biocompatible Heterogeneous Catalyst 
Encouraged by the vast possibilities and applications of palladium chemistry
1
 the 
preparation of a “bio-friendly” internalisable Pd
0
–based heterogeneous catalyst was 
undertaken. This was achieved by the application of two technologies. Firstly, the 
use of microsphere (500nm) mediated cellular delivery that has previously been used 
in both cellular labelling and intracellular delivery of biomaterials, showing 
remarkable cellular biocompatibility and exonuclear localization.
160-164
 Secondly, the 
application of palladium nanoparticles entrapped within cross-linked resin beads that 





3.5.1  Synthesis of Pd
0
-microspheres139 
This catalyst-loaded delivery system was synthesized as shown in Figure 3.1. 
Amino-functionalized polystyrene microspheres (500nm, loading 0.08mmol) were 
used as  a solid support as well as a delivery agent.
161
 The amino-functionalised the 
microspheres were treated with Pd(OAc)2 in toluene at 80°C for 10 min followed by 
3 hours at room temperature to ensure maximum uptake and interaction with 
microspheres. The electron-rich microsphere network binds Pd
2+
 ions of Pd(OAc)2 
by coordination to the free amino groups and aromatic rings. The coordinated Pd
2+
 
was subsequently trapped by extensive cross-linking with the bis acid chloride of 





 with 10% hydrazine hydrate in methanol gave black beads (due to the 
trapped Pd
0 






Figure 3.1 Synthesis of Pd
0
-microspheres via immobilisation of palladium 




-microspheres were kept in water and stored at 4
o
C as a grey 
suspension (Figure 3.2), and were characterised and tested for catalytic activity, 





-microspheres. Left: Naked amino-functionalised microspheres 
(milky-white solution) and Right: Pd
0
-microspheres (grey suspension). 
 
3.5.2  Characterisation of the Pd
0
-microspheres 
3.5.2.1   Scanning Electron Microscopy (SEM) 
The morphology of the dried Pd
0
-microspheres was determined using SEM (Philips 
XL30CP0) with gold coating by sputtering. The images of the Pd
0
-microspheres 
showed there was no physical change in terms of size, shape and surface following 
entrapment (Figure 3.3). 
 
   
 
Figure 3.3 SEM images of Pd
0
-microspheres (0.5 µm) at different magnifications. 




3.5.2.2   HR-Tranmission Electron Microscopy (TEM) 
The size and distribution of the Pd
0
 nanoparticles on microspheres was analysed 
using TEM (JEM-2011), and the TEM images of the Pd
0
-microspheres (Figure 3.4) 
were compared with naked-microspheres. Analysis showed the Pd
0
 nanoparticles to 




Figure 3.4 Transmission Electron Microscopy (TEM) of Pd
0
-microsphere at two 
different magnifications: (A) naked microspheres, (B) Pd
0
 nanoparticles are 






3.5.3 Palladium Analysis 
3.5.3.1 Quantitative palladium analysis: Inductively Coupled Plasma-Optical 
Emission Spectrometer (ICP-OES) 
The presence of Pd
0
 in the Pd
0
-microspheres was measured by ICP-OES. Dried Pd
0
-
microspheres (50 mg) were dissolved in DCM and shaken for 24 hours. Due to the 
“solubilization” of the microspheres, the palladium nanoparticles were released from 
the support and collected by centrifugation. The supernatant was collected and this 
procedure repeated to ensure all Pd
0
 nanoparticles were collected. After washing 
several times with DCM, palladium analysis was carried out by using ICP-OES with 
calibration against standard palladium solutions. Analysis gave a blank value of 0.30 
ppm. The levels of Pd
0
 obtained from 50 mg dried Pd
0
-microspheres was determined 
as 22.35 ppm, which equates to 4.2 x 10
-6
 moles of Pd
0
 per g of beads (0.45 mg of 
Pd
0




 one single bead 
contains 0.45
 
/ 1.52 x 10
13 




 (2.78 x 10
-16
 moles or about 20 
millions atoms). 
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3.5.3.2 Qualitative Palladium Analysis: Powder X-Ray diffraction (XRD) 
Qualitative Pd
0
 analysis was carried out by powder X-ray diffraction (XRD). X-ray 
powder diffraction is most widely used for the identification of unknown crystalline 
materials (e.g. minerals and inorganic compounds). XRD is a rapid analytical 
technique primarily used for phase identification of a crystalline material. Dried Pd
0
-
microspheres (50 mg) were analysed on a Philips PW1800. The spectra were 
compared with Pd
0
 standard (commercially available) and microspheres alone. The 
reflection peaks seen in an XRD pattern (Figure 3.5) at 2 around 40.1, 46.6 and 
68.3
o
 corresponds to the (111), (200) and (220) planes of an fcc (face-centered cubic) 
lattice respectively. All data matches the data for Pd
0
 provided by the ASTM 


















3.6  Investigating Catalytic Activity of Pd
0
-Microspheres  
The allyloxycarbonyl (Alloc) protecting group is often used to protect a hydroxyl or 
amino group when an orthogonal deprotection is required. To demonstrate the 
catalytic activity of the Pd
0
-microspheres, the bis-allyloxycarbonyl rhodamine 110 
(28), used by Meggers was synthesised.
150
 Protection on both sides forces the 
molecule to adopt a closed, colorless and nonfluorecent lactone (Scheme 3.1).  
 
 




3.6.1 Alloc Deprotection in Solution 
The catalytic activity of the Pd
0
-microspheres were tested in solution under different 
conditions using bis-allyloxycarbonyl rhodamine 110 (28). This fluorophore is non-
fluorescent, however upon allylcarbamate deprotection, strong green-fluorescent 





-microsphere induced allylcarbamate cleavage. 
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The reaction progress was monitored with TLC and LCMS to confirm 
conversion of 27. This experiment was the important test to evaluate catalytic 
activity of Pd
0
-microspheres before its use for intracellular catalysis.  As shown in 
Figure 3.6, after 24 hours reaction, green fluorescence (indicating the presence of 
uncaged rhodamine 110, 27) was clearly observed from the reactions containing Pd
0
-
microspheres, while no fluorescence was observed from the negative control and in 
the absence of Pd
0
-microspheres. Surprisingly, the reaction also occurred without 
presence of thiophenol which is known to be harmful to the living cell.
150
  This 
suggested the deprotection only occurred with presence of Pd(0) as well as evidence 
of catalytic activity.   
 
 




-microsphere were used for allylcarbamate cleavage of compound 28. 
The images was taken under UV illumination shows (A) negative control, (B) 
reaction containing Pd
0





3.7 Cellular Uptake Study 
Although the microspheres have shown remarkable cellular compatibility and have 
been widely used as a highly efficient cellular delivery vehicle for a variety of 
materials,
160, 162-164
 the presence of Pd
0
 on the beads required an investigation of their 
biological compatibility. Cellular uptake of Pd
0
-microspheres was tested on HeLa 
cells (human cervical cancer) for 24 hours and analysed by flow cytometry analysis 
and confocal microscopy. In order to track Pd
0
-microspheres inside the cell, Pd
0
-
microspheres were labelled with dyes through the free amino group. Labelling of the 
Pd
0
-microspheres was realized by deprotection of the Fmoc group and subsequent 
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treatment with an ‘’activated dye” under basic conditions (Scheme 3.3). Two 
different dyes were used for analytical reasons: Cy5.5 for flow cytometry analysis 




Scheme 3.3 Synthesis of fluorescently Pd
0
-microspheres labelled with dyes. 
 
3.7.1 Flow Cytometry Analysis.  
Flow cytometric techniques allow quantification of cellular fluorescence. After 
incubation with beads, cells were washed twice with PBS, harvested with 
trypsin/EDTA and resuspended in 2% FCS in PBS. The internalization of labelled-
microspheres was analyzed by flow cytometry. In order to distinguish between 
internalized Pd
0
-microspheres and those on the extracellular membrane of cells, flow 
cytometry was performed in the solution in the presence of trypan blue (Ex/Em = 
520/650nm) which quenches fluorescence and labeled beads 
(fluorescence/rhodamine 110). Quantification by flow cytometry showed the clear 
presence of Texas Red (610/20 band pass filter) (Figure 3.7) and Cy5.5 (Figure 3.8) 
signal under the 780/60 band pass filter.  
 50 
 
Figure 3.7 Flow cytometry analysis of (A) unlabelled Pd
0





Figure 3.8 Flow cytometry analysis of (A) untreated HeLa cells and (B) HeLa cells 





3.7.2 Confocal Microscopy Studies 
Confocal microscopy has the ability to collect a series of optical sections from thick 
specimens and analyse them in a 3D manner. Cellular uptake of Texas Red-labelled 
Pd
0
-microspheres was further corroborated by confocal imaging. The presence of 
Texas Red labelled Pd
0
-microspheres showed that Pd
0
-microspheres were indeed 




Figure 3.9 HeLa cells containing Texas Red-labelled Pd
0
-microspheres (in red) as 
viewed under a confocal microscope. The nucleus is shown in blue and the 
membrane in purple. 
 
3.8 Cytoxicity of Pd
0
-Microspheres 
The possibility of Pd
0
-microsphere cytotoxicity was evaluated. This is perhaps the 
most important test to investigate if the Pd
0
-microspheres are truly heterogeneous or 
not. Pd not trapped on the microspheres may leach out from the solid support and be 
toxic to the cells. However, extensive cross-linking should prevent leakage.  
Cytotoxicity associated with the Pd
0
-microspheres was determined using both MTT 
(3-(4,5-dimethylthiozol-2-yl)2,5-diphenyl tetrazolium bromide) and propidium 
iodide assays.  
 
3.8.1 MTT Assay 
Cytotoxicity of Pd
0
-microspheres was assessed by the use of an MTT assay
166
 which 
is a quantitative colorimetric method that determines cell viability. It is based on 
cellular metabolism and reduction of the tetrazolium salt (MTT) to form an insoluble 
formazan dye mediated by cellular microsomal enzymes only produced by live cells 
(Scheme 3.4). 
 
Scheme 3.4 Metabolism of the "succinate-tetrazolium reductase". 
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Cytotoxicity tests were carried out on the cell line HeLa. Cells were plated in 
a 96-well plate with a density of 5,000 cells/well and left to grow for 24 hours. Two 
concentrations of Pd
0
-microspheres were studied (0.25 L/100 L (C1, 0.19x10
10
 





added to the well and incubated with the cells for 48 hours. Each condition was 
carried out in triplicate, with cells growth monitored under a microscope. After 
incubation, the general protocol for the cytotoxicity test was carried out and results 
compared to untreated cells. Figure 3.10 shows the cell viability of HeLa cells 
treated with Pd
0
-microspheres at two concentrations with no substantial cytotoxicity 
noted within error.  
 




 beads/mL), (C2 
0.38x10
10
 beads/mL)) on HeLa cells. 
 
3.8.2 Counting and Replating   
This experiment was carried out to investigate the behaviour of cells containing Pd
0
-
microspheres after detachment from the well surface by trypsination. The ability of 
the cells to reattach was observed and used as a cell viability study (modified cell 
viability assay by Rossignol et al.).
167
 HeLa cells were diluted in RPMI-CM (1 mL) 
with a density of 40,000 cells/well, plated in a 12 well plate and grown for 24 hours. 
Pd
0




 beads/mL) were added to the well plates and incubated for another 24 
hours. The media was removed, the cells were washed with PBS (10 mM) and then 
detached with trypsin (2.5% in EDTA) for 5 min at 37
o
C. The cells were diluted with 
1 mL of media, counted by phase contrast microscopy using trypan blue, and then 
replated for 1 hour. The number of cells in suspension after 1 hour was quantified by 
phase contrast microscopy using trypan blue for extracellular quenching (in 










cells at the beginning of the experiment. 
b.





Number of cells in the suspension after 1 hour of replating. 
Viable cells should have reattached. 
 Cells plated
a
 No. of Cells 36 h
b
 













































-mediated Allyl-carbamate Cleavage in Living 
Cells 
In 2006, Meggers described a water-soluble ruthenium complex that rapidly entered 
cells and performed an allylcarbamate cleavage of bis-N-allyloxycarbonyl rhodamine 
110 (28), which were non-toxic to cells during the short duration (minutes) of the 
experiment.
150
 The use of a purely heterogeneous catalyst in the form of an “artificial 
organelle” would allow the long-term cytoplasmic presence of metals without 
toxicity (many transition metals; including palladium;
155





-microspheres, would allow the exploration of challenging 
metal-catalyzed reactions inside a cell.   
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3.9.1 Allylcarbamate Cleavage in HeLa Cells 
In order to assess allylcarbamate cleavage, cells were loaded with fluorescently-
labelled Pd
0
-microspheres for 24 hours and subsequently washed to eliminate 
extracellular Pd
0
-microspheres. Fresh media containing 30µM bis-allyloxycarbonyl 
rhodamine 110 (28) was incubated with the cells. The lipophilic nature of the non-
fluorescent compound 28 allows its cellular internalization (Scheme 3.5), while 
allylcarbamate cleavage results in the liberation of the strongly fluorescent 
rhodamine 110 (27, = 0.91, Ex/Em: 498/521nm).  
 
 
Scheme 3.5 Intracellular Pd
0
-mediated allylcarbamate cleavage in HeLa cells. 
 
3.9.2 Analysis by Flow Cytometry 
In this experiment, Cy5.5 labelled-Pd
0
-microspheres were used. The intracellular 
presence of Cy5.5 labelled-Pd
0
-microspheres and fluorescent compound 27 were 
determined by flow cytometry (with appropriate control) using different band pass 
emission filters (780/60 and 530/30, respectively).  
 
Figure 3.11 showed cytograms of Pd
0
 catalysis of allylcarbamate cleavage. 
Untreated cells, a control treated with only the Pd
0
-microspheres or incubated just 




-microsphere loaded HeLa cells incubated with reagent 28 showed 
fluorescence emission under both Cy5.5 (indicating the presence of the Pd
0
-
microspheres) and FITC-like band pass filters (associated with the deprotection of 
dye 27), showing for the first time Pd
0
-mediated catalysis inside a cell.  It is 
noteworthy that the Pd
0
-microspheres did not require any exogenous co-factor (e.g. 
thiophenol which is know to be toxic to living cells) to assist catalysis of the 
reaction, but of course cells contain the thiol gluthatione, which would be an ideal 
co-factor.  
      
Figure 3.11 Cytograms showing Pd
0
 catalysis of allylcarbamate cleavage: y-axis 
represents Cy5.5 fluorescence intensity (band pass emission filter: 780/60nm) and 
the x-axis the FITC-like intensity of the cell (band pass emission filter: 530/30nm). 
(A) Untreated cell control. (B) Cells after 24h incubation with Cy5.5-Pd
0
-
microspheres. (C) Cells after 24h incubation with reagent 28. (D) Pd
0
-microsphere 
loaded cells after 24h incubation with reagent 28. 
 
In addition, Figure 3.12a to 3.12d, showed cytograms and histograms the 
uptake of Cy5.5-labelled Pd
0
-microspheres (780/60 emission band pass filter) and the 





Figure 3.12a Untreated HeLa cells. 
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Figure 3.12c Cells treated with reagent 28 (30 µM). 
 
 
Figure 3.12d Cells treated with Cy5.5-labelled Pd
0
-microspheres and   
 reagent 28 (30 µM). 
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3.9.3 Analysis by Confocal Microscopy 
The intracellular presence of Pd
0
-microspheres and the fluorescent compound 27 was 
further corroborated by confocal imaging. After reaction, cells were washed and 
fixed with 4% formaldehyde in PBS for 30 min at room temperature.
168
 During 
fixing the whole contents of the cell essentially become “locked in place” due to 
extensive cross-linking between free amino groups. Nuclei were stained with 
Hoeschst 33342. As shown in Figure 3.13, confocal microscopy verified the 
simultaneous presence of fluorescently-labelled Pd
0
-microspheres and intracellular 




Figure 3.13 Merged confocal image of a single HeLa cell showing a Hoechst 33342-
stained nucleus (blue), Texas Red-labelled Pd
0
-microspheres (red) and deprotected 
compound 27 (green). Microscope settings: excitation laser lines at 488, 543 and 
595nm, with emission filters of 385–470nm for Hoechst 33342, 505–530nm for 








3.9.4    In-vitro Study 
The presence of thiophenol on cleavage efficiency was investigated since it is known 
to increase the conversion of allyl carbamate cleavage.
150
 The presence of 
biomolecules (e.g. cell lysate or glutathione) on the efficiency of allylcarbamate 
cleavage was also explored (Table 3.2). Glutathione was also evaluated as it is 
naturally present in all mammalian cells.
169
 A range of solvents were also used. The 
catalytic activity of the Pd
0
-microspheres was clearly enhanced by the presence of 
glutathione (5mM), with turnover numbers per-palladium atom up to 30 in the 
presence of cell extract and glutathione. Meanwhile, the addition of PhSH (entry 17-
20) or GSH (entry 21-24) and the combination of GSH and PhSH (entry 25-28) did 
not show any increase of 27.  
 


















1 PBS - - - - n/a 
2 RPMI - - - - n/a 
3 Cell 
extract 
- - - - n/a 
4 DMF - - - - n/a 
5 PBS + - - - 0 
6 RPMI + - - - 0 
7 Cell 
extract 
+ - - - 0 
8 DMF + - - - 0 
9 PBS + - + - 0 
10 RPMI + - + - 0 
11 Cell 
extract 
+ - + - 0 
12 DMF + - + - 0 
13 PBS + + - - 3 
14 RPMI + + - - 3 
15 Cell 
extract 
+ + - - 3 
16 DMF + + - - 3 
17 PBS + + - + 3 
18 RPMI + + - + 3 
19 Cell 
extract 
+ + - + 3 
20 DMF + + - + 3 
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21 PBS + + + - 21 
22 RPMI + + + - 21 
23 Cell 
extract 
+ + + - 22 
24 DMF + + + - 21 
25 PBS + + + + 21 
26 RPMI + + + + 21 
27 Cell 
extract 
+ + + + 21 
28 DMF + + + + 21 
 
3.9.5 Recycling Test of Pd
0
-microspheres 
Recycled microspheres from within the cells (after a reaction) were tested in solution 
to determine that they were still catalytically active. Pd
0
-microspheres were collected 
from the cell lysate after a catalytic reaction had occurred. The beads were washed 
with water (3 times), DMF (3 times) and methanol (3 times) then collected by 
centrifugation at 13000 rpm for 3 minutes. The Pd
0
-microspheres were used for an in 
vitro experiment of allylcarbamate cleavage. As shown in Table 3.3, the recycled 
Pd
0
-microspheres showed a slightly lower conversion relative to freshly prepared 
Pd
0
-microspheres, however this can be explained by some loss of Pd
0
-microspheres 
during the recovery process from the cells. 
 
Table 3.3 In vitro experiments of allylcarbamate cleavage: freshly-prepared Pd
0
-
microspheres (entry 1-4) vs. recycled Pd
0






















1 PBS + + - + 21 








4 DMF + + - + 21 
5 PBS + - + + 16 




+ - + + 19 
8 DMF + - + + 17 
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3.9.6 LC-MS and HPLC Analysis of Allylcarbamate Cleavage in HeLa Cells 
The characterization of the reaction products formed in cells were determined by the 
purification and analysis of the cell lysate which quantitatively confirmed chemical 
identities via LC-MS and HPLC. In order to have enough 27 to be analysed by MS 
and HPLC, the reaction was carried out on 3 million HeLa cells. After reaction, the 
cells were washed extensively with PBS to remove any extra cellular material, the 
cells were detached with Trypsin-EDTA, lysed with water and by subsequent 
sonication and the lysate was centrifuged for 5 min at 13,000 rpm. The supernatant 
was collected and passed through a DSC-18LT column which had been pre-washed 
with water. The column was washed with water to remove salts and proteins from the 
cell lysate, and acetonitrile was used to elute the desired product 27 from the column.  

The residue was dissolved in methanol and analysed by LCMS in positive 
ionization mode. LCMS suggested the presence of rhodamine 110 (27) with the mass 
found 331.0 (Figure 3.14).  In addition, HPLC analysis of the cell lysate showed a 
retention times with a sample standard of 27 at around 3.2 minutes (Figure 3.15).  
 
 
Figure 3.14 LCMS analysis from the cell lysate confirming the presence of 
rhodamine 110, 27. 
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Figure 3.15 HPLC analysis of standard rhodamine 110 (left) absorbance at 495nm 
was compared with cell lysate (right). 
 
3.10 Making C–C Bonds within Cells 
Encouraged by the allylcarbamate cleavage in a living cell, research was expanded to 
a more challenging reaction. The Suzuki-Miyaura cross-coupling of arylboronates or 
esters with aryl halides (or triflates) in the presence of Pd
0
 permits ready access to a 
spectacular range of biaryls.
129, 130
 To explore the intracellular formation of a carbon-
carbon cross-coupled product, an unambiguous fluorescence-detectable cell-based 
experiment was designed, based on palladium mediated synthesis of a fluorescent 
dye (anthofluorescein, 3)
73
 via an aryl-aryl cross-coupling reaction (Scheme 3.6).  
 
 
Scheme 3.6 Anthofluorescein (3) was synthesised via palladium-catalyzed cross-




3.10.1 Synthesis Anthofluorescein in Living Cells 
Suzuki palladium-catalyzed cross-coupling of fluorescein mono-triflate (2) with p-
hydroxyphenylboronic acid was expected to give anthofluorescein within the cells. 
However, a preliminary study found the existence of a high background due to the 
3’-(trifluoromethanesulfonyl)fluorescein, 2 (λex = 488nm, λem = 510nm), which 
made cell analysis by confocal microscopy or FACS analysis difficult (overlapping 
with anthofluorescein).  
 
To address this problem, a non-fluorescent mono-triflate (29) was 
synthesized. A methyl group was introduced into 6’- position of 3’-
(trifluoromethanesulfonyl)fluorescein to lock the fluoran polycycle into the lactone. 
The installation of the methyl group forced the generation of the ring closed, 
colorless and nonfluorecent lactone form 29, therefore eliminating any fluorescent 
background (Scheme 3.7). This was synthesised by alkylation of 2 with methyl 
iodide at 150
o
C for 60 minutes resulting colorless compound 29.  
 
 




3.10.2 Designing Fluorescent Small Molecule that Target the 
Mitochondria 
One of the main problems in designing small molecule/reagents for intracellular 
catalysis is the ability for them to stay within the cell over time and a general 
procedure for quantification either by flow cytometry or confocal microscopy.  
Leaching out of cross-coupled products from the cells may cause difficulties during 
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cell analysis. In addition, a turn-on emission increase or shift in excitation/emission 




The presence of the triphenylphosphonium moiety (a lipophilic cation) is 
known to promote direct accumulation several hundred-fold within mitochondria.
170
 
Molecules were designed both to turn-on fluorescence after reaction and target the 
mitochondria by introducing a triphenylphosphonium moiety (30) in the boronic acid 
(31) to form compound 32 (Scheme 3.8).  
 
 
Scheme 3.8 Synthesis of Synthesis of (4-(4’-(pinacolatoboron)phenylamino]butyl)- 
triphenyl phosphonium bromide (32). 
 
 
3.10.3 Synthesis of (4-(4’-(3’’-methoxyfluoran-6’’-
yl)phenylamino]butyl)triphenyl phosphonium bromide (33) 
In vitro synthesis of compound 33 was carried out to allow an investigation of its 
fluorescent and localisation properties (Scheme 3.9). The cross-coupling of non-
fluorescent mono-triflate 29 and the alkylaminophenylboronate 32 should “unlock” 
the disrupted conjugation of the fluoran polycycle 29 by opening of the lactone, 





















Scheme 3.9 Synthesis of (4-(4’-(3’’-methoxyfluoran-6’’-yl)phenylamino] 
butyl)triphenyl phosphonium bromide, 33. 
 
3.10.4 Study of the Fluorescent Properties of Dye 33 
Optical properties of dye 33 were investigated by spectrophotometric analysis. The 
quantum yield of compound 33 was calculated as 0.32. Spectrophotometric analysis 
showed that absorbance of 33 (10 µM) (Figure 3.16). Meanwhile, emission spectra 
of compound 33 (1em = 520 – 540nm) has a broad and slightly red-shift emission 
(Figure 3.17), which will partially overlap with the Texas-Red emission spectra.  
 
 
Figure 3.16 Absorption spectra of 10µM solution of 33 (20% glycerol in water).  
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Figure 3.17 Emission spectra of 33 with excitation at 480nm (1 µM, 20% glycerol in 
water); Ex/Em = 480/520nm. 
 
3.10.5 Hydrolytically Stable Compound 29 
Hydrolytically stable of 29 was further investigated by synthesising the hydrolysed 















Scheme 3.10 Synthesis of hydrolysed product, 6’-(methyl)fluorescein 34. 
 
In order to investigate the hydrolytic stability of 29, compound 29 was stirred 
in PBS at 37
o
C for 48. After reaction, the formation of 34 was analysed using HPLC. 
The result showed a retention times corresponded to compound 29 at around 3.7 
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minutes. In contrast, no formation of 34 was observed where the retention time at 
around 4.2 minutes (section 4.3.4.4), suggesting compound 29 is hydrolytically 
stable in the experiment condition used (Figure 3.18). Meanwhile, cell based 
experiment in different conditions were carried out to investigate hydrolytic stable of 
29 (section 3.10.6.1, 3.10.7 and 3.10.8).  
 
Figure 3.18 HPLC analysis showed the peak of compound 29 at 3.7 minutes, while 




-mediated Intracellular Synthesis in HeLa Cells  
HeLa cells Pre-loaded with Cy5.5-labelled Pd
0
-microspheres were incubated with 20 
M of cell permeable compound 29 and 32. After 48 hours, cross-coupling of these 
compounds catalysed by Pd
0
 would form dye 33 and at the same time localising into 





3.10.6.1 Flow cytometry analysis 
After incubation, cells were washed twice with PBS, harvested with trypsin/EDTA 
and resuspended in 2% FCS in PBS buffer. The intracellular presence of Cy5.5-
labelled Pd
0
-microspheres and compound 33 was determined by flow cytometry 
under different band pass emission filters (780/60 and 576/26, respectively). As 
shown in Figure 3.19, only the cells treated with Cy5.5-labelled Pd
0
-microspheres, 
reagent 29 and 32 were fluorescent under both emission filters, indicating the Pd-
mediated synthesis of compound 33. Figure 3.20a to 3.20d showed cytograms and 
histograms showing the uptake of Cy5.5-labelled Pd
0
-microspheres (780/60 emission 
band pass filter) and the synthesis of the Suzuki cross-coupled dye 33 (576/26 
emission band pass filter) in HeLa cells (section 4.3.4.6). 
 
Figure 3.19 Cytograms showing the uptake of Cy5.5-labelled Pd
0
-microspheres, (A) 
Untreated cells, (B) Cell treated with Pd
0
-microspheres and reagents 29 and 32, (C) 
Cell treated with Pd
0
-microspheres, (D) Cells treated with Pd
0
-microspheres and 29. 
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                                                      Concentration of 33                   Concentration of 33 
 




        Concentration of 33                   Concentration of 33 
 





          Concentration of 33                   Concentration of 33 
 
Figure 3.20c Cells treated with reagent 29 (20 µM) and 32 (20 µM). 
 
 
            Concentration of 33                   Concentration of 33 
 
Figure 3.20d Cells treated with Pd
0
-microspheres labelled with Texas red, reagents 




These results showed that the Pd
0
 beads and both reagents (29 and 32) are 
needed in order to generate the new product 33 (x-axis). Controls were carried out, 
both in solution and in cell experiments, to rule out the possibility of any 
fluorescence seen being the result of hydrolysed mono-triflate (34), indeed mono-
triflate was remarkably robust surviving changed in the presence of the Pd
0
-
microspheres for over 48 hours. 
3.10.6.2 Confocal microscopy 
Flow cytometry studies were corroborated with confocal microscopy (section 
4.3.4.7). After reaction, the cell were washed with PBS and stained with Hoechst 
33342 as well as with a mitochondria stain in order to prove accumulation dye 33 in 
the mitochondria. Figure 3.21 shows deconvolved confocal images of a single cell 
under different filters. 
 
Figure 3.21 Deconvolved confocal image of a single cell. (A) Cell nucleus (blue) 
and mitochondria (red). (B) Cell nucleus (blue) and in cellulo synthesised compound 
33 (green). (C) Merged (orange indicates colocalization). (D) Merged image of the 
same cell observed from a different angle. White arrow indicates the presence of a 
Pd
0
-microsphere, which was imaged under 550/20 emission filter along with 
compound 33 and did not localize within mitochondria.  
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Due to the broad excitation/emission spectra of Texas Red, both the Suzuki-
Miyaura product 33 and the Texas Red-labelled were imaged under the same 
fluorescent channel. The Pd
0
-microspheres could be identified as they did not co-
localize with the mitochondria tracker dye or the nucleus stain, thus corroborating 
their cytoplasmatic location (Figure 3.22). As expected, cellular experiments 
verified that, compound 33 exclusively localised within the mitochondria.  
 
Since Texas red has a very broad emission spectra it was possible to image 
Texas red labelled Pd
0
-microspheres both with the emission filter 540-560 and 595-
615nm. Due to partial overlap between compound 33 and Texas Red emission 
spectra, both 33 and Pd
0
-microspheres were imaged under the 540-560nm emission 
filter (Figure 3.22b). Under the emission filter 595-615nm the Pd
0
-microspheres 
were imaged while compound 33 was not, enabling us to distinguish fluorescence 
originating between Pd
0
-microspheres and compound 33 (Figure 3.22a).  
 
Figure 3.22 Showing 3D deconvolved image of the same cell after processing the 
confocal pictures. (A) Texas Red –labelled Pd
0
-microspheres in the emission channel 
(green), cell nucleus (blue), and fluorescently-stained mitochondria (red). (B) 
Merged images showed Texas Red-labelled Pd
0
-microspheres did not localise with 
the mitochondria tracker dye or the nuclei dye, thus corroborating their 






3.10.7 In Vitro Experiments 
In vitro experiments of the Suzuki-Miyaura cross-coupling (Table 3.4) were carried 
out in PBS, DMF and cell extract. There was no visible conversion of compound 29 
to 6’-methylfluorescein (34) in the presence or absence of Pd
0
 under a variety of 
conditions. On the other hand, the presence of Pd
0
 showed the formation of 33 due to 
the cross-coupling between 29 and 32 (entries 17 – 20).  
 









(10 L 3.4 µM pd0) 
Yield of 
33 (%) 
1 PBS - - - n/a 
2 RPMI - - - n/a 
3 Cell extract - - - n/a 
4 DMF - - - n/a 
5 PBS + - - n/a 
6 RPMI + - - n/a 
7 Cell extract + - - n/a 
8 DMF + - - n/a 
9 PBS + + - 0 
10 RPMI + + - 0 
11 Cell extract + + - 0 
12 DMF + + - 0 
13 PBS + - + n/a 
14 RPMI + - + n/a 
15 Cell extract + - + n/a 
16 DMF + - + n/a 
17 PBS + + + 22 
18 RPMI + + + 21 
19 Cell extract + + + 22 




3.10.8 LC-MS and HPLC Analysis of Suzuki Product (33) in HeLa 
Cells 
The characterization of the reaction products formed in cells was carried out by the 
purification and analysis of the cell lysate which quantitatively confirmed chemical 
identities via MS and HPLC. The cells lysate was prepared as previous described 
(section 3.9.6). A DSC-18LT column was used to flush the non-desired products 
from the column, and the product eluted with 10% MeOH in DCM. The residue was 
analysed by LC-MS (Figure 3.23) gave the mass 738.2 corresponding to 33 and the 
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mass of compound 32 was found 536.2, which is known to be able to accumulate 
directly into mitochondria without undergoing reaction. While it was not possible to 
determine the overall quantity of unreacted boronate 32, the identification of 
compound 32 in the extracts suggests that 32 was in excess in the mitochondria.  
Compound 29 or its hydrolysed derivative 34 were not detected.  
 
 
Figure 3.23 LCMS analysis from cell lysate confirming the presence compound 33. 
 
This result was corroborated by HPLC analysis confirmed the retention time 
peaks of dye 33 and cells lysate at around 3.8 minutes (Figure 3.24).     
 
 
                   Compound 33                                            Cell lysate 
 





In conclusion, the first Pd
0
-based heterogeneous catalyst with the ability to cross cell 
membranes, stay harmlessly within the cytoplasm for days, and carry out for the first 
time artificial chemistry has been described. The Pd
0
-microsphere catalyst was 
successfully prepared by immobilising Pd
0
 nanoparticles in the microspheres through 
electronic interactions between the electron-rich of the aryl rings of microspheres and 
Pd
2+ 
atoms followed by extensive cross-linking with the bis acid chloride of racemic 
Fmoc-Glutamate. Pd
2+
 were reduced to Pd
0







-microspheres are catalytically active based on Alloc 
deprotection in solution with and without presence of thiophenol. Furthermore, the 
Pd
0
-microspheres are able to penetrate the cell membrane after 24 hours incubated 
with HeLa cells. Meanwhile cytotoxicity tests indicated low levels of toxicity (<4%) 
and good cell viability (>90%) after 48 hours of contact with the Pd
0
-microspheres.   
 
This engineered “pseudo-organelle” demonstrated intracellular catalytic 
activity of an unnatural metal towards exogenous materials. Pd
0
-microspheres were 
successfully used to perform intracellular catalysis both deprotection and C-C 
formation, such as the Alloc deprotection and a Suzuki–Miyaura cross-coupling 
reaction (fluorophore synthesis).   
 
This investigation provides the basis for the customization of heterogeneous 
unnatural catalysts as tools for creative applications in chemical biology (such as in 
situ labelling of cellular structures), pharmacology (for example, in cellulo pro-drug 
activation of hydrophilic molecules with low cell penetrability for functional 
screening in cellular disease models) and, potentially, in medicine (for example, the 
systemic administration of a pro-drug with local activation via implant-captured 









4.1    General Information 
4.1.1    Chemicals  
All solvents and reagents were obtained from commercial suppliers and used without 
purification, unless otherwise stated.  
 




C NMR spectra were recorded on a Bruker ava-500 (500 and 75 MHz, 
respectively) in the solvents indicated at 298 K. Chemical shifts are reported on the 
 scale in ppm using the residual non-deuterated solvent as the internal standard or 
the 
13
C natural abundance of the deuterated solvent. Coupling constants (J) are 
reported in Hz. Low Resolution Mass Spectra (LRMS) were obtained using a 
Hewlett Packard LCMS 1100 ChemStation with a G1946B mass detector, equipped 
with an electrospray ion source. High Resolution Mass Spectra (HRMS) was 
performed using Bruker 3.0 T Apex II Spectrometer. Thin layer chromatography 
(TLC) was performed using Alugram SIL G/UV/254 precoated plates. UV/Vis 
measurement was performing on an Agilent 8453 spectrophotometer. Column 
chromatography was performed on silica gel using Keiselgel 60, 230-400 mesh ( 
Merck). Infrared (IR) spectra were obtained on a Fourier transform IR Bruker 
Tensor 27 Spectrometer. All samples were run neat and frequencies are reported in 
cm
-1
. Only frequencies corresponding to significant functional groups are reported. 
Reverse phase analytical HPLC (RP HPLC) was performed using an Agilent 1100 
Chemstation, and compounds were detected using an ELSD detector. All solvents 
used were HPLC grade. Preparative reverse phase-HPLC purifications were 
performed on an Agilent Technologies HP1100 Chemstation eluting with (A) 
H2O/0.1% TFA and (B) CH3CN/0.1% TFA on a Waters X-Terra C-18 preparative 
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column (150 mm x 19 mm, 5 m), at a flow rate of 5 mL/min. The following 
gradient was used: 100% (A) to 40% (B) over 5 min, 40% to 70% (B) over 20 min, 
70% to 100% (B) over 4 min, with detection by UV at 214, 254 and 440 nm. 
Microwave assisted heating was carried out by irradiating the mixture in a Biotage 
Initiator at 2.45 GHz. Scanning Electron Microscopy (SEM) images were obtained 
on a Philips XL30CP SEM with a X-ray analysis and HKL channel Electron 
Backscatter Diffraction (EBSD) system on samples coated with a thin layer of gold, 
to a depth of approximately 20 nm, under vacuum. High Resolution Transmission 
Electron Microscopy (HR-TEM) analyses were conducted on a JEM-2011 (JEOL, 
200Kv) at the Electron Microscopy Laboratory in the School of Chemistry, 
EastChem University of St Andrews. X-ray powder diffraction (XRD) spectra were 
taken on a Philips PW1800. Inductively coupled plasma atomic emission 
spectrometry (ICP-OES) was obtained on a Perkin Elmer Optima 5300 DV 
ICPOES sensitive between 0.0002-1000ppm. Fluorescence spectra were recorded 
on a Jobin Yvon SPEX Fluoromax, using 1cm path length fused silica cuvettes. Live 
HeLa cells were monitored using an x20 objective Leica fluorescence microscope 
under brightlight and 488nm excitation. Flow cytometry analysis was carried out on 
a Becton Dickinson (BD) FACS Aria
TM
 using FACSDivaTM or FlowJo software. 
The absorbance of 96-well plates was read on a Benchmark Bio-Rad microplate 
reader at 570nm using the Microplate manager 4.0 software. Confocal images were 
taken on a Leica SP5 confocal microscope and Zeiss 510 Meta software was used for 
digital acquisition. Deconvolution was carried out using AutoQuant X software.  
 
4.1.3    Biological Section 
Media, sera and antibiotics were purchased from Gibco or Sigma-Aldrich. Cell 
culture was performed in a 5% CO2 atmosphere at 37°C in a SteriCult 200 (Hucoa-
Erloss) incubator. HeLa cells were cultured in RPMI media supplemented with 10% 
fetal bovine serum (FBS), glutamine (4 mM) and antibiotics (penicillin and 
streptomycin, 100 units/mL). The day before the assay, cells were washed with 
phosphate buffered saline (PBS), detached with trypsin/EDTA, counted, and diluted 
with media to the appropriate concentration. 
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4.2 Experimental for Chapter 2  
4.2.1    Synthesis of 3´-(trifluoromethanesulfonyl)fluorescein (2)73   
 
Fluoroscein 1 (536 mg, 1.6 mmol), N-phenyl-bis(trifluoromethanesulfonimide) (644 
mg, 1.80 mmol) and potassium carbonate (322 mg, 2.40 mmol) were stirred in dry 
DMF (16 mL) and microwave-irradiated at 80 °C for 20 minutes. The reaction 
mixture was partitioned between EtOAc (120 mL) and 1M HCl (80 mL), the aqueous 
layer was extracted with EtOAc (2 x 30 mL), and the combined organics dried 
(MgSO4) and reduced in vacuo. Purification of the residue via chromatography on 
silica gel (4:1 Hex:EtOAc) afforded 3´-(trifluoromethanesulfonyl)fluorescein as an 
off-white solid (453 mg, 0.98 mmol, 61%). M.p.: 160-162
o
C; IR: ν= cm-1: 3385.08, 
1735, 1609, 1420, 1207, 1206, 1137, 1106; 
1
H NMR (500 MHz, DMSO-d6) δ 10.33 
(1H, s, OH), 8.07 (1H, d, J 7.1 Hz, ArH), 7.87-7.74 (2H, m, ArH), 7.72 (1H, d, J 2.5 
Hz, ArH), 7.39 (1H, d, J 7.3 Hz, ArH), 7.26 (1H, dd, J 8.8 Hz, 2.6 Hz, ArH), 7.04 
(1H, d, J 8.9 Hz, ArH), 6.78 (1H, s, ArH), 6.66 (2H, s, ArH). 
13
C NMR (75 MHz, 
DMSO-d6) δ 168.01 (C=O), 159.49 (C), 151.74 (C), 151.14 (C), 150.77 (C), 149.18 
(C), 135.61 (CH), 130.24 (CH x2), 128.74 (CH), 125.23 (C), 124.59 (CH), 123.69 
(CH), 119.55 (C), 116.78 (CH), 113.20 (CH), 110.28 (CH), 108.35 (C), 101.93 (CH), 
80.83 (C); MS (ES
+
): m/z 465.0 [100, (M+H)
+
]; HRMS calcd for C21H11F3O7S: 
464.0178, found: 464.0192 ; RP HPLC tR = 4.9 minutes (100% purity, ELSD); 






4.2.2    Synthesis of 3´-hydroxy-6´-(p-hydroxyphenyl)fluoran, (3)73 
 
3´-(trifluoromethanesulfonyl)fluorescein (186 mg, 0.40 mmol), 4-hydroxyphenyl 
boronic acid (66 mg, 0.48 mmol), palladium acetate (5 mg, 0.02 mmol) and 
triphenylphosphine (21 mg, 0.08 mmol) were stirred in degassed dioxane (10 mL). 
Potassium carbonate (83 mg, 0.60 mmol) in water (1 mL) was added and the 
resulting mixture was microwave irradiated at 120 °C for 30 minutes. For 
heterogeneous catalysis using polystyrene resin captured palladium (XL-RC Pd
0
). 
3´-(trifluoromethanesulfonyl)fluorescein (186 mg, 0.40 mmol), 4-hydroxyphenyl 
boronic acid (66 mg, 0.48 mmol), potassium carbonate (83 mg, 0.60 mmol) and XL-
RC Pd
0
 (180 mg, 5%mmol) were stirred in water (2mL) microwave irradiated at 120 
°C for 10 minutes. The reaction mixture was partitioned between EtOAc (50 mL) 
and 1 M HCl (40 mL), the aqueous layer was extracted with EtOAc (2 x 20 mL) and 
the combined organics dried (MgSO4) and concentrated in vacuo. Purification of the 
residue via chromatography on silica gel (4:1 Hex:EtOAc) afforded the 
anthofluorescein as a dark red solid (127 mg, 0.31 mmol, 78%). M.p.: 133-135
o
C; 
IR: ν= cm-1: 3438, 2971, 1759, 1599, 1420, 1199, 1100; 1H NMR (500 MHz, 
CD3OD) δ 8.03-8.00 (1H, m, ArH), 7.79-7.66 (2H, m, ArH), 7.51-7.47 (3H, m, 
ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, m, ArH), 6.79 (2H, d, J 
8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 (1H, d, J 2.3 Hz, ArH), 6.56-6.45 
(2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 171.54 (C=O), 161.25 (C=O), 159.08 
(C), 154.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 131.91 (C), 
131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 125.87 (CH), 
125.27 (CH), 123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 115.30 (CH), 
113.65 (CH), 111.08 (CH), 103.67 (C); MS (ES
+
): m/z 409.1 [100, (M+H)
+
]; HRMS 
calcd for C26H16O5: 408.0998, found: 408.1358; RP HPLC tR = 4.7 minutes (100% 
purity, ELSD); Φ: 0.30 (pH 8, 20% glycerol); Ex/Em: 530/570nm.  
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4.2.3    Synthesis of 3´-acetyloxy-6´-(p-acetyloxyphenyl)fluoran (4)73  
 
3´-hydroxy-6´-(p-hydroxyphenyl)fluoran (30 mg, 0.07 mmol) was stirred in acetic 
anhydride:pyridine (1:1, 2 mL) for 16 hours. The solvent was reduced in vacuo and 
the residue was partitioned between EtOAc (10 mL) and 1M HCl (5 mL). The 
organic layer was dried (MgSO4) and reduced in vacuo. Purification of the residue 
via chromatography on silica gel (5:1 Hex:EtOAc) afforded 3´-acetyloxy-6´-(p-
acetyloxyphenyl)fluoran as a white solid (30 mg, 0.061 mmol, 87%). M.p.: 158-
160
o
C; IR: ν= cm-1: 3205, 3053, 1728, 1605, 1428, 1251, 1111;  1H NMR (500 MHz, 
CD3OD) δ 8.06-8.03 (1H, m, ArH), 7.78-7.67 (2H, m, ArH), 7.66-7.62 (2H, m, 
ArH), 7.54 (1H, d, J 1.8 Hz, ArH), 7.32 (1H, dd, J 8.3 Hz, 1.8 Hz, ArH), 7.18-7.15 
(4H, m, ArH), 6.87-6.83 (3H, m, ArH), 2.28 (3H, s, CH3), 2.25 (3H, s, CH3); 
13
C 
NMR (75 Hz, CD3OD) δ 171.10 (C=O), 171.0 (C=O), 170.50 (C=O), 154.50 (C), 
153.80 (C), 153.00 (C), 152.60 (C), 152.40 (C), 144.40 (C), 138.10 (C), 136.90 
(CH), 131.50 (CH), 130.00 (CH), 129.50 (CH), 129.20 (CH), 127.30 (C), 126.10 
(CH), 125.10 (CH), 123.90 (CH), 123.30 (CH), 119.10 (CH), 118.90 (C), 117.70 (C), 





]; HRMS calcd for C30H20O7: 492.1209, found: 492.1201; RP 
HPLC tR = 4.4 minutes (100% purity, ELSD). 
 
4.2.4    Cell Labelling/viability Assay 
35 µL of a 0.25 mM solution of compound 3 (PBS:DMSO, 99:1 v/v) were added to 
the corresponding well containing HeLa cells (total volume = 350 µL, final 
concentration of 3´-acetyloxy-6´-(p-acetyloxyphenyl)fluoran (25 µM) and incubated 
for 2h (37°C and 5% CO2). The culture medium was removed, the cells were washed 
twice with PBS and phenol red-free media added. HeLa cells were imaged using a 
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x20 objective (Leica fluorescence microscope) under brightlight and 488nm 
excitation.  
 
4.2.5    Toxicity Studies 
Cytotoxicity tests were carried out on HeLa cells in triplicate for 2, 4 and 8 hours. 
Cells were plated in a 24-well plate at a density of 10,000 cells/well and left to grow 
for 24 hours. Aliquots of the compound under investigation (25 µM) were added and 
cells monitored under a fluorescent microscope. After incubation (2 hr, 4 hr and 8 hr) 
media was replaced with 360 L of fresh media (phenol red free) along with 40 L 
of 3-(4,5-dimethylthiozol-2-yl)2,5-diphenyl tetrazolium bromide), MTT (5 mg/mL) 
and the cells incubated for 3 hours at 37°C. After the incubation the resulting 
formazan crystals were dissolved by adding 300 µL of MTT solubilisation solution. 
The absorbance was measured spectrophotometrically at a wavelength of 570 nm and 
results compared to untreated cells. 
 
4.2.6    Absorbance Studies 
Absorption spectra were recorded on a Varian Cary-300 spectrometer using 1cm 
pathlength fused silica cuvettes. The spectral bandwidth was 2nm. Fluorescence 
spectra were recorded on a SPEX Fluoromax, using 1cm pathlength fused silica 
cuvettes. The excitation and emission slits were 7nm. 
 
4.2.7 Excitation/Emission Analysis 
Fluorescence spectra were recorded on a SPEX Fluoromax, using 1cm pathlength 









4.2.8    Synthesis of Anthofluorescein Derivative 




3´-(Trifluoromethanesulfonyl)fluorescein, 2,  (186 mg, 0.40 mmol), boronic acid, X 
(0.48 mmol), palladium acetate (4.5 mg, 0.02 mmol) and triphenylphosphine (21 mg, 
0.08 mmol) were stirred in degassed dioxane (10 mL). Potassium carbonate (83 mg, 
0.60 mmol) in water (1 mL) was added and the resulting mixture was microwave 
irradiated at 120 °C for 30 minutes. The reaction mixture was partitioned between 
EtOAc (50 mL) and 1 M HCl (40 mL), the aqueous layer was extracted with EtOAc 
(2 x 20 mL) and the combined organics dried (MgSO4) and concentrated in vacuo. 
Purification of the residue via chromatography on silica gel (4:1 Hex:EtOAc) or (1:9 
MeOH:DCM) for compounds 19 and 20. 
 
4.2.8.1    Synthesis of 2-(3-(benzo[d][1,3]dioxol-5-yl)-6-oxo-6H-xanthen-9-
yl)benzoate (5) 
 
X = (3,4-Methylenedioxyphenyl)boronic acid, afforded 5 as dark red solid (135 mg, 
0.31 mmol, 78%). M.p.: 145-148
o
C; IR: ν= cm-1: 3213, 2923, 2358, 1728, 1606, 
1405, 1200,1112; 
1
H NMR (500 MHz, CD3OD): 2 = 8.09-8.07(1H, m, ArH), 7.85-
7.81 (2H, m, ArH), 7.61 (1H, dd, J 8.3 Hz, 1.8 Hz, ArH), 7.37-7.32 (3H, m, ArH), 
7.24-7.21 (1H, m, ArH), 7.02 (1H, d, J 8.2 Hz, ArH), 6.79 (2H, d, J 8.6 Hz, ArH), 
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6.63 (2H, d, J 2.3 Hz, ArH), 6.50-6.01 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 
170.28 (C=O), 168.56 (C=O), 159.62 (C), 152.41 (C), 151.70 (C), 150.91 (C), 
148.24 (C), 135.58 (CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 
129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 
116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 100.64 (C), 82.23 
(CH2); MS (ES
+
): m/z 437.1 [100, (M+H)
+
]; HRMS calcd for C27H16O6: 437.0947, 
found: 437.1027 ; RP HPLC tR = 3.8 minutes (100% purity, ELSD); Φ: 0.51; Ex/Em: 
480/532nm. 
 
4.2.8.2   Synthesise  2-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-6-oxo-6H-
xanthen-9-yl)benzoic acid (6) 
 
X = 1,4-Benzodioxane-6-boronic acid, afforded 6 as dark red solid (131 mg, 0.29 
mmol, 73%). M.p.: 134-136
o
C; IR: ν= cm-1: 3308, 3021, 1760, 1559, 1430, 1110; 1H 
NMR (500 MHz, CD3OD): 2 = 8.04-8.03 (1H, m, ArH), 7.81-7.74 (2H, m, ArH), 
7.59-7.23 (3H, m, ArH), 7.23 (1H, dd, J 8.3 Hz, 1.8 Hz, ArH), 7.17-7.14 (1H, m, 
ArH), 6.78 (1H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.5 Hz, ArH), 6.65 (1H, d, J 2.3 
Hz, ArH), 6.56-6.45 (2H, m, ArH), 4.28 (4H, s, ArH); 
13
C NMR (75 MHz, CD3OD) 
δ 171.54 (C=O), 165.25 (C=O), 159.60 (C), 154.39 (C), 152.01 (C), 149.08 (C), 
145.24 (C), 135.65 (CH), 132.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 
129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 
116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 103.67 (C), 64.11 
(CH2), 64.00 (CH2); MS (ES
+
): m/z 451.1 [100, (M+H)
+
]; HRMS calcd for 
C28H18O6: 450.1103, found: 450.1111; RP HPLC tR = 4.3 minutes (100% purity, 





 4.2.8.3   Synthesis (3-(2,3-dihydrobenzofuran-6-yl)-6-oxo-6H- xanthen-9-yl) 
benzoic acid (7) 
 
 
X = 2,3-Dihydrobenzofuran-5-boronic acid, afforded 7 as dark red solid (131 mg, 
0.30 mmol, 75%). M.p.: 127-131
o
C; IR: ν= cm-1: 3361, 2957, 1755, 1594, 1450, 
1216, 1100; 
1
H NMR (500 MHz, CD3OD): 2 = 8.04-8.01 (1H, m, ArH), 7.79-7.66 
(2H, m, ArH), 7.51-7.47 (3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-
7.14 (1H, m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 
(1H, d, J 2.3 Hz, ArH), 6.56-6.45 (2H, m, ArH), 4.13 (t, J = 6.3 Hz, 4H, OCH2CH2); 
13
C NMR (75 MHz, CD3OD) δ 171.24 (C=O), 164.24 (C=O), 159.08 (C), 154.62 
(C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 
130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 
123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 
111.08 (CH), 103.67 (C), 64.14 (CH2), 60.03 (CH2); MS (ES
+
): m/z 435.1 [100, 
(M+H)
+
]; HRMS calcd for C28H18O5: 434.1154, found: 434.1163; RP HPLC tR = 4.5 
minutes (100% purity, ELSD); Φ: 0.49; Ex/Em: 482/528nm.  
 
4.2.8.4   Synthesis of 2-(3-(1H-indol-6-yl)-6-oxo-6H-xanthen-9-yl)benzoic acid (8) 
 
X = 5-Indolylboronic acid, afforded 8 as dark red solid (121 mg, 0.28 mmol, 70%). 
M.p.: 130-133
o
C; IR: ν= cm-1: 3338, 2961, 1760, 1559, 1430, 1178, 1110; 1H NMR 
(500 MHz, CD3OD): 2 = 8.04-8.08 (1H, m, ArH), 7.81-7.64 (2H, m, ArH), 7.51-7.47 
(3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, m, ArH), 6.79 
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(2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.68 (1H, d, J 2.3 Hz, ArH), 
6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 171.54 (C=O), 161.25 
(C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 
131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 
115.30 (CH), 113.65 (CH), 111.08 (CH), 103.67 (C); MS (ES
+
): m/z 432.1 [100, 
(M+H)
+
]; HRMS calcd for C28H17NO4: 431.1158, found: 431.1241 ; RP HPLC tR = 
3.6 minutes (100% purity, ELSD); Φ: 0.47; Ex/Em: 480/531nm. 
 




X = 1-Methyl-1H-indole-5-boronic acid, afforded 9 as dark red solid (138 mg, 0.31 
mmol, 78%). M.p.: 140-142
o
C; IR: ν= cm-1: 3265, 3012, 1746, 1559, 1380, 1189, 
1090; 
1
H NMR (500 MHz, CD3OD): 2 = 8.03-8.01 (1H, m, ArH), 7.79-7.66 (2H, m, 
ArH), 7.51-7.47 (3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, 
m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.59 (1H, d, J 2.3 
Hz, ArH), 6.56-6.45 (2H, m, ArH), 3.75 (CH3); 
13
C NMR (75 MHz, CD3OD) δ 
171.34 (C=O), 162.25 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 (C), 
145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 
129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 
116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 103.67 (C), 52.32 
(CH3); MS (ES
+
): m/z 446.1 [100, (M+H)
+
]; HRMS calcd for C29H19NO4: 445.1314, 





4.2.8.6   Synthesis of 2-(3-(furan-2-yl)-6-oxo-6H-xanthen-9-yl)benzoic acid (10) 
 
X = 2-Furanylboronic acid, afforded 10 as orange solid (96 mg, 0.25 mmol, 63%). 
M.p.: 137-141
o
C; IR: ν= cm-1: 3230, 3092, 1720, 1605, 1390, 1120, 1100; 1H NMR 
(500 MHz, CD3OD): 2 = 8.04-8.02 (1H, m, ArH), 7.82-7.78 (2H, m, ArH), 7.51-7.47 
(3H, m, ArH), 7.31 (1H, dd, J 8.2 Hz, 1.8 Hz, ArH), 7.27-7.13 (1H, m, ArH), 6.79 
(2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.56-6.45 (2H, m, ArH); 
13
C 
NMR (75 MHz, CD3OD) δ 170.44 (C=O), 165.24 (C=O), 159.08 (C), 154.62 (C), 
154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 
(CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 
(CH), 118.15 (C), 116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH); 
MS (ES
+
): m/z 383.1 [100, (M+H)
+
]; HRMS calcd for C24H14O5: 382.0841, found 
382.1205; RP HPLC tR = 3.7 minutes (100% purity, ELSD); Φ: 0.45; Ex/Em: 
482/533nm. 
 




X = 2-Thienylboronic acid, afforded 11 as yellow solid (140 mg, 0.35 mmol, 88%). 
M.p.: 126-130
o
C; IR: ν= cm-1: 3280, 3010, 1760, 1559, 1430, 1178, 1110; 1H NMR 
(500 MHz, CD3OD): 2 = 8.03-8.00 (1H, m, ArH), 7.92-7.79 (2H, m, ArH), 7.41-7.45 
(3H, m, ArH), 7.31 (1H, dd, J 8.2 Hz, 1.8 Hz, ArH), 7.24-7.13 (1H, m, ArH), 6.79 
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(2H, d, J 8.6 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.56-6.45 (2H, m, ArH); 
13
C 
NMR (75 MHz, CD3OD) δ 170.44 (C=O), 165.24 (C=O), 159.08 (C), 154.62 (C), 
154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 
(CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 
(CH), 118.15 (C), 116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH); 
MS (ES
+
): m/z 399.1 [100, (M+H)
+
]; HRMS calcd for C24H14O4S: 398.0613, found 
398.0454; RP HPLC tR = 4.1 minutes (100% purity, ELSD); Φ: 0.46; Ex/Em: 
477/528nm. 
 
4.2.8.8    Synthesis of 2-(3-(benzofuran-2-yl)-6-oxo-6H-xanthen-9-yl)benzoic acid 
(12) 
 
X = 2-Benzofuranylboronic acid, afforded 12 as pale orange solid (139 mg, 0.32 
mmol, 80%). M.p.: 155-157
o
C; IR: ν= cm-1: 3338, 2990, 1730, 1590, 1430, 1178, 
1110; 
1
H NMR (500 MHz, CD3OD): 2 = 8.04-8.00 (1H, m, ArH), 7.82-7.76 (2H, m, 
ArH), 7.51-7.47 (3H, m, ArH), 7.31 (1H, dd, J 8.3 Hz, 1.8 Hz, ArH), 7.37-7.14 (1H, 
m, ArH), 6.83 (2H, d, J 8.6 Hz, ArH), 6.86 (1H, d, J 8.3 Hz, ArH), 6.65 (1H, d, J 2.3 
Hz, ArH), 6.46-6.41 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 170.64 (C=O), 
164.23 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.58 (C), 145.24 (C), 138.68 
(CH), 136.91 (C), 135.19 (CH), 133.18 (CH), 132.33 (CH), 131.28 (CH), 128.92 (C), 
127.87 (CH), 126.27 (CH), 124.04 (CH), 119.15 (C), 118.82 (CH), 117.70 (C), 
116.30 (CH), 115.65 (CH), 109.08 (CH), 100.67 (C); MS (ES
+
): m/z 433.1 [100, 
(M+H)
+
]; HRMS calcd for C28H16O5: 432.0998, found: 432.1025;  RP HPLC tR = 4.9 




4.2.8.9    Synthesis of 2-(3-(benzo[b]thiophen-2-yl)-6-oxo-6H-xanthen-9-
yl)benzoic acid (13) 
 
X = Benzo[b]thien-2-ylboronic acid, afforded 13 as pale orange solid (140 mg, 0.31 
mmol, 78%). M.p.: 157-160
o
C; IR: ν= cm-1: 3305, 3010, 1760, 1570, 1395, 1170, 
1020; 
1
H NMR (500 MHz, CD3OD): 2 = 8.03-8.00 (1H, m, ArH), 7.92-7.88 (2H, m, 
ArH), 7.51-7.47 (3H, m, ArH), 7.31 (1H, dd, J 8.3 Hz, 1.8 Hz, ArH), 7.37-7.14 (1H, 
m, ArH), 6.83 (2H, d, J 8.6 Hz, ArH), 6.86 (1H, d, J 8.3 Hz, ArH), 6.70 (1H, d, J 2.3 
Hz, ArH), 6.46-6.41 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 171.94 (C=O), 
163.93 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.58 (C), 145.24 (C), 138.68 
(CH), 136.91 (C), 135.19 (CH), 133.18 (CH), 132.33 (CH), 131.28 (CH), 128.92 (C), 
127.87 (CH), 126.27 (CH), 124.04 (CH), 119.15 (C), 118.82 (CH), 117.70 (C), 
116.30 (CH), 115.65 (CH), 112.08 (CH), 101.67 (C); MS (ES
+
): m/z 449.1 [100, 
(M+H)
+
]; HRMS calcd for C28H16O4S: 448.0769, found: 448.1325; RP HPLC tR = 
3.7 minutes (100% purity, ELSD); Φ: 0.40; Ex/Em: 479/538nm. 
 
 
4.2.8.10 Synthesis of 2-(3-oxo-6-phenyl-3H-xanthen-9-yl)benzoic acid (14) 
 
 
X = 4-phenylboronic acid, afforded 14 as pale yellow (106 mg, 0.27 mmol, 68%). 
M.p.: 150-153
o
C; IR: ν= cm-1: 3284, 2950, 1778, 1540, 1380, 1178, 1126; 1H NMR 
(500 MHz, CD3OD): 2 = 8.03-8.00 (1H, m, ArH), 7.79-7.66 (2H, m, ArH), 7.51-7.47 
(3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, m, ArH), 6.79 
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(2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.62 (1H, d, J 2.3 Hz, ArH), 
6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 171.54 (C=O), 161.25 
(C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 
131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 
115.30 (CH), 113.65 (CH), 111.08 (CH), 108.67 (C); MS (ES
+
): m/z 393.0 [100, 
(M+H)
+
]; HRMS calcd for C26H16O4: 392.1049, found: 392.1052; RP HPLC tR = 3.9 
minutes (100% purity, ELSD); Φ: 0.30; Ex/Em: 470/535nm. 
 




X = Pyrene-1-boronic acid, afforded 15 as pink solid (129 mg, 0.25 mmol, 63%). 
M.p.: 145-148
o
C; IR: ν= cm-1: 3338, 2960, 1760, 1559, 1430, 1178, 1110; 1H NMR 
(500 MHz, CD3OD): 2 = 8.26-8.24 (2H, m, ArH), 8.19-8.18 (1H, m, ArH), 8.12-7.96 
(7H, m, ArH), 7.84-7.81 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.76-7.73 (1H, m, ArH), 
7.55-7.54 (1H, m, ArH), 7.34 (2H, d, J 8.7 Hz, ArH), 6.97 (1H, d, J 8.3 Hz, ArH), 
6.77 (1H, d, J 2.3 Hz, ArH), 6.70 (1H, d, J 2.3 Hz, ArH) 6.61 (1H, d, J 2.3 Hz, ArH); 
13
C NMR (75 MHz, CD3OD) δ 171.54 (C=O), 161.25 (C=O), 159.08 (C), 154.62 
(C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 131.91 (C), 130.08 (C), 
129.62 (C), 128.01 (C), 127.08 (C), 125.24 (C),  124.19 (CH), 124.14 (CH), 123.33 
(CH), 122.28 (CH), 121.92 (C), 119.87 (CH), 118.27 (CH), 117.04 (CH), 115.15 (C), 
114.82 (CH), 113.70 (C), 112.30 (CH), 110.65 (CH), 108.08 (CH), 103.68 (C); MS 
(ES
+
): m/z 515.0 [100, (M+H)
+
]; HRMS calcd for C36H20O4: 516.1362, found, 
516.1235; RP HPLC tR = 4.4 minutes (100% purity, ELSD); Φ: 0.32; Ex/Em: 
477/525nm. 
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4.2.8.12 Synthesis of 2-(3-(4-(dimethylamino)phenyl)-6-oxo-6H-xanthen-9-
yl)benzoic acid (16) 
 
 
X = 4-(Dimethylamino)phenylboronic acid, afforded 16 as purple solid (136 mg, 
0.30 mmol, 75%). M.p.: 160-163
o
C; IR: ν= cm-1: 3238, 3068, 1760, 1559, 1430, 
1170, 1110; 
1
H NMR (500 MHz, CD3OD): 2 = 8.03-8.00 (1H, m, ArH), 7.79-7.66 
(2H, m, ArH), 7.51-7.47 (3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-
7.14 (1H, m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 
(1H, d, J 2.3 Hz, ArH), 6.56-6.45 (2H, m, ArH), 3.75 (CH3), 3.71 (CH3) ; 
13
C NMR 
(75 MHz, CD3OD) δ 171.54 (C=O), 161.25 (C=O), 159.08 (C), 154.62 (C), 154.01 
(C), 153.08 (C), 145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 
129.33 (CH), 129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 
118.15 (C), 116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 
103.67 (C), 54.23 (CH3), 52.45 (CH3); MS (ES
+
): m/z 452.1 [100, (M+H)
+
]; HRMS 
calcd for C28H21NO4: 435.1471, found: 435.1487; RP HPLC tR = 3.9 minutes (100% 
purity, ELSD); Φ: 0.30; Ex/Em: 475/530nm. 
 





X = 4-(Dimethylamino)phenylboronic acid, afforded 17 as pale yellow solid (140 
mg, 0.33 mmol, 83%). M.p.: 152-155
o
C; IR: ν= cm-1: 3330, 2966, 1760, 1559, 1430, 
1178, 1110; 
1
H NMR (500 MHz, CD3OD): 2 = 8.05-8.01 (1H, m, ArH), 7.89-7.74 
(2H, m, ArH), 7.61-7.58 (3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-
7.14 (1H, m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 
(1H, d, J 2.3 Hz, ArH), 6.56-6.45 (2H, m, ArH), 3.26 (CH3); 
13
C NMR (75 MHz, 
CD3OD) δ 173.54 (C=O), 164.25 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 
(C), 145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 
129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 
116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 103.67 (C), 55.34 
(CH3); MS (ES
+
): m/z 423.1 [100, (M+H)
+
]; HRMS calcd for C27H18O5: 422.1154, 
found: 422.1023;  RP HPLC tR = 3.8 minutes (100% purity, ELSD); Φ: 0.23; Ex/Em: 
470/532nm. 
 
4.2.8.14 Synthesis of 2-(3-(3-methoxyphenyl)-6-oxo-6H-xanthen-9-yl)benzoic 
acid (18) 
 
X = 3-(Dimethylamino)phenylboronic acid, afforded 18 as pale yellow solid (131 
mg, 0.31 mmol, 78%). M.p.: 143-137
o
C; IR: ν= cm-1: 3274, 2998, 1706, 1502, 1422, 
1178, 1158; 
1
H NMR (500 MHz, CD3OD): 2 = 8.03-8.00 (1H, m, ArH), 7.89-7.74 
(2H, m, ArH), 7.61-7.58 (3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-
7.14 (1H, m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 
(1H, d, J 2.3 Hz, ArH), 6.56-6.45 (2H, m, ArH), 3.24 (CH3); 
13
C NMR (75 MHz, 
CD3OD) δ 173.54 (C=O), 164.25 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 
(C), 145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 
129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 
116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 103.67 (C), 54.21 
(CH3); MS (ES
+
): m/z 423.0 [100, (M+H)
+
]; HRMS calcd for C27H18O5: 422.1154, 
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found: 422.1025; RP HPLC tR = 3.8 minutes (100% purity, ELSD); Φ: 0.22; Ex/Em: 
478/533nm. 
 
4.2.8.15 Synthesis of 2-(3-(4-carboxyphenyl)-6-oxo-6H-xanthen-9-yl)benzoic 
acid (19) 
 
X = 4-Carboxyphenylboronic acid, afforded 19 as yellow solid (149 mg, 0.34 mmol, 
85%). M.p.: 162-164
o
C; IR: ν= cm-1: 3338, 2961, 1760, 1559, 1430, 1178, 1110; 1H 
NMR (500 MHz, CD3OD): 2 = 8.12-8.09 (1H, m, ArH), 7.69-7.56 (2H, m, ArH), 
7.51-7.47 (3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, m, 
ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.75 (1H, d, J 8.3 Hz, ArH), 6.71 (1H, d, J 2.3 
Hz, ArH), 6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 171.54 (C=O), 
161.25 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 
(CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 
115.30 (CH), 113.65 (CH), 111.08 (CH), 104.64 (C); MS (ES
+
): m/z 437.0 [100, 
(M+H)
+
]; HRMS calcd for C27H16O6: 436.0947, found: 436.1221; RP HPLC tR = 4.3 
minutes (100% purity, ELSD); Φ: 0.29; Ex/Em: 480/532nm. 
 






X = 3-Carboxyphenylboronic acid, afforded 20 as yellow solid (139 mg, 0.32 mmol, 
80%). M.p.: 129-133
o
C; IR: ν= cm-1: 3305, 3012, 1762, 1548, 1430, 1207, 1165; 1H 
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NMR (500 MHz, CD3OD): 2 = 8.03-8.00 (1H, m, ArH), 7.79-7.66 (2H, m, ArH), 
7.51-7.47 (3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, m, 
ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 (1H, d, J 2.3 
Hz, ArH), 6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 170.34 (C=O), 
161.25 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 
(CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 
115.30 (CH), 113.65 (CH), 111.08 (CH), 103.67 (C); MS (ES
+
): m/z 437.1 [100, 
(M+H)
+
]; HRMS calcd for C27H16O6: 436.0947, found: 436.0956; RP HPLC tR = 3.7 
minutes (100% purity, ELSD); Φ: 0.29; Ex/Em: 480/530nm. 
 
4.2.8.17   Synthesis of 2-(3-oxo-6-(4-(trifluoromethyl)phenyl)-3H-xanthen-9-
yl)benzoic acid (21) 
 
X = 4-(trifluoromethyl)phenylboronic acid, afforded 21 as pale yellow solid (124 mg, 
0.27 mmol, 68%). M.p.: 130-134
o
C; IR: ν= cm-1: 3338, 2961, 1760, 1559, 1430, 
1178, 1110; 
1
H NMR (500 MHz, CD3OD): 2 = 8.07-8.04 (1H, m, ArH), 7.79-7.66 
(2H, m, ArH), 7.51-7.44 (3H, m, ArH), 7.21 (1H, dd, J 8.4 Hz, 1.9 Hz, ArH), 7.14-
7.12 (1H, m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.60 
(1H, d, J 2.3 Hz, ArH), 6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 
171.50 (C=O), 165.75 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 (C), 
145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 
129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 
116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 103.67 (C); MS 
(ES
+
): m/z 461.1 [100, (M+H)
+
]; HRMS calcd for C27H15F3O4: 460.0922, found: 




4.2.8.18 Synthesis of 2-(3-oxo-6-p-tolyl-3H-xanthen-9-yl)benzoic acid (22) 
 
 
X = 4-methylphenylboronic acid, afforded 22 as orange solid (126 mg, 0.31 mmol, 
78%). M.p.: 138-143
o
C; IR: ν= cm-1: 3280, 2998, 1728, 1570, 1421, 1125, 1106; 1H 
NMR (500 MHz, CD3OD): 2 = 8.09-8.06 (1H, m, ArH), 7.83-7.68 (2H, m, ArH), 
7.63-7.52 (3H, m, ArH), 7.31 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.14-7.09 (1H, m, 
ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 (1H, d, J 2.3 
Hz, ArH), 6.56-6.45 (2H, m, ArH), 2.25 (CH3); 
13
C NMR (75 MHz, CD3OD) δ 
171.54 (C=O), 161.25 (C=O), 159.08 (C), 154.62 (C), 154.01 (C), 153.08 (C), 
145.24 (C), 136.68 (CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 
129.28 (CH), 127.92 (C), 125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 
116.82 (CH), 116.70 (C), 115.30 (CH), 113.65 (CH), 111.08 (CH), 109.67 (C), 53.45 
(CH3); MS (ES
+
): m/z 407.1 [100, (M+H)
+
]; HRMS calcd for C27H18O4: 406.1205, 
found: 406.1001; RP HPLC tR = 3.9 minutes (100% purity, ELSD); Φ: 0.27; Ex/Em: 
478/529nm. 
 




X = 4-nitrophenylboronic acid, afforded 23 as yellow solid (140 mg, 0.32 mmol, 
80%). M.p.: 158-160
o
C; IR: ν= cm-1: 3301, 3008, 1702, 1530, 1178, 1098; 1H NMR 
(500 MHz, CD3OD): 2 = 8.03-8.00 (1H, m, ArH), 7.79-7.66 (2H, m, ArH), 7.51-7.47 
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(3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, m, ArH), 6.79 
(2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.68 (1H, d, J 2.3 Hz, ArH), 
6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 170.86 (C=O), 164.66 
(C=O), 158.70 (C), 153.62 (C), 152.71 (C), 152.08 (C), 145.24 (C), 136.68 (CH), 
131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 123.04 (CH), 120.15 (C), 118.82 (CH), 118.70 (C), 
117.30 (CH), 115.65 (CH), 114.08 (CH), 108.44 (C); MS (ES
+
): m/z 438.0 [100, 
(M+H)
+
]; HRMS calcd for C26H15NO6: 437.0899, found: 437.1041; RP HPLC tR = 
3.5 minutes (100% purity, ELSD); Φ: 0.21; Ex/Em: 482/531nm. 
 
4.2.8.20 Synthesis of 2-(3-(4-cyanophenyl)-6-oxo-6H-xanthen-9-yl)benzoic acid 
(24) 
 
X = 4-Cyanophenylboronic acid, afforded 24 as pale yellow solid (125 mg, 0.30 
mmol, 75%). M.p.: 124-127
o
C; IR: ν= cm-1: 3338, 2961, 2242, 1760, 1430, 1178, 
1110; 
1
H NMR (500 MHz, CD3OD): 2 = 8.10-8.08 (1H, m, ArH), 7.86-7.80 (2H, m, 
ArH), 7.85-7.67 (3H, m, ArH), 7.44 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.44-7.13 (1H, 
m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 (1H, d, J 2.3 
Hz, ArH), 6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 170.47 (C=O), 
162.24 (C=O), 160.21 (C), 155.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 
(CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 
115.30 (CH), 114.44 (CH), 112.08 (CH), 107.07(C); MS (ES
+
): m/z 418.1 [100, 
(M+H)
+
]; HRMS calcd for C27H15NO4: 417.1001, found 417.1132; RP HPLC tR = 




4.2.8.21   Synthesis of 2-(3-(4-chlorophenyl)-6-oxo-6H-xanthen-9-yl)benzoic acid 
(25) 
 
X = 4-Chlorophenylboronic acid, afforded 25 as pale yellow solid (111 mg, 0.26 
mmol, 65%). M.p.: 164-167
o
C; IR: ν= cm-1: 3238, 3061, 1720, 1495, 1430, 1178, 
830; 
1
H NMR (500 MHz, CD3OD): 2 = 8.09-8.06 (1H, m, ArH), 7.86-7.80 (2H, m, 
ArH), 7.85-7.67 (3H, m, ArH), 7.44 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.44-7.13 (1H, 
m, ArH), 6.79 (2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 (1H, d, J 2.3 
Hz, ArH), 6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 171.47 (C=O), 
162.24 (C=O), 160.21 (C), 155.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 
(CH), 131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 123.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 
115.30 (CH), 114.44 (CH), 112.13 (CH), 105.22(C); MS (ES
+
): m/z 427.0 [100, 
(M+H)
+
]; HRMS calcd for C26H15ClO4: 426.0659, found 426.0854; RP HPLC tR = 
3.9 minutes (100% purity, ELSD); Φ: 0.13; Ex/Em: 470/535nm. 
 
4.2.8.22 Synthesis of 2-(3-(4-aminophenyl)-6-oxo-6H-xanthen-9-yl)benzoic acid 
(26) 
 
X = 4-aminoyphenyl boronic acid, afforded 26 as yellow solid (118 mg, 0.29 mmol, 
73%). M.p.: 156-160
o
C; IR: ν= cm-1: 3320, 3052, 1698, 1547, 1430, 1110; 1H NMR 
(500 MHz, CD3OD) δ 8.03-8.00 (1H, m, ArH), 7.79-7.66 (2H, m, ArH), 7.51-7.47 
(3H, m, ArH), 7.21 (1H, dd, J 8.3 Hz, 1.9 Hz, ArH), 7.17-7.14 (1H, m, ArH), 6.79 
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(2H, d, J 8.7 Hz, ArH), 6.70 (1H, d, J 8.3 Hz, ArH), 6.65 (1H, d, J 2.3 Hz, ArH), 
6.56-6.45 (2H, m, ArH); 
13
C NMR (75 MHz, CD3OD) δ 170.36(C=O), 161.35 
(C=O), 158.68 (C), 154.62 (C), 154.01 (C), 153.08 (C), 145.24 (C), 136.68 (CH), 
131.91 (C), 131.19 (CH), 130.18 (CH), 129.33 (CH), 129.28 (CH), 127.92 (C), 
125.87 (CH), 125.27 (CH), 124.04 (CH), 118.15 (C), 116.82 (CH), 116.70 (C), 
115.30 (CH), 113.65 (CH), 111.08 (CH), 105.65 (C); MS (ES
+
): m/z 409.1  ; HRMS 
calcd for C26H17NO4: 407.1158, found: 407.0981; RP HPLC tR = 4.5 minutes (100% 
purity, ELSD); Φ: 0.26; Ex/Em: 476/532nm. 
 
4.2.9 Cell labelling/viability Assay Compound 9 
Solution of compound 9 (PBS: DMSO, 99:1 v/v) were added to the well containing 
HeLa cells (total concentration 5 µM) and incubated for 2h (37°C and 5% CO2). The 
culture medium was removed, the cells were washed twice with PBS. HeLa cells 
were imaged using a x20 objective (Leica fluorescence microscope) under brightlight 
and 488nm excitation.  
 
4.3 Experimental for Chapter 3 
 
4.3.1    Synthesis and Characterization of Pd
0
-microspheres139 
4.3.1.1    Synthesis of Fmoc-Glu(Cl)-Cl 
DMF (186L, 2.7 mmol) and thionyl chloride (360 µL, 5.4 mmol) were added to a 
suspension of Fmoc-Glu(OH)-OH (1.00 g, 2.7 mmol) in DCM (10 mL). The reaction 
mixture was stirred and heated at reflux for 8h, then the reaction was cooled to room 
temperature and the solvents removed under reduced pressure to afford the 
corresponding acid chloride (1.10g crude) which was used immediately for the next 
step.  
 
4.3.1.2    Cross-linked Pd
0
-microspheres 
1.0 mL of aminomethyl polystyrene microspheres (0.5 µm, 0.08 mmol/g, 4% SC) 
was placed in an eppendorf and the solvent (water) removed by centrifugation at 
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13,000 rpm for 5 minutes and subsequently washed with DMF (1 mL) and Toluene 
(2 x 1 mL). Palladium acetate (0.2 mg) in toluene (0.5 mL) was added to the beads. 
The eppendorf was placed in an oven (80°C) for 2 minutes and then sonicated, this 
procedure was repeated 5 times, and then shaken at room temperature for 2 hours to 
give a light-brown mixture. The beads were washed with toluene (3 x 1 mL) and 
methanol (1 mL) to ensure excess palladium acetate was removed. The cross-linking 
agent mixture (10mg of Fmoc-Glu(Cl)-Cl) and 11 µL triethylamine in 1.0 mL of dry 
DMF) was added to the Pd
2+
-microsperes and shaken at room temperature for 1 hour. 
This step was repeated to afford 100% cross-linking. Following washing with 
methanol (3 x 0.5 mL) and water (3 x 0.5 mL) the microspheres gave a negative 
ninhydrin test (indicating full coupling of the microsphere amino groups with the 
cross-linking agent). Hydrazine in Methanol (10 %) was added to the Pd
2+
-











4.3.1.3    Preparation of Pd
0
-microspheres labelled with Texas Red  
Fmoc deprotection was carried out using 20% piperidine in MeOH (1h) and the 
resulting amine-free Pd
0
-microspheres washed with DMF (3 x 1 mL). Subsequently, 
a solution of Texas Red in DMF (0.5 mg (5 equiv.) 1 mL) and diisopropylethylamine 
(DIPEA, 1 µL, 10 equiv.) were sequentially added and the resulting mixture shaken 
for 24 hours. The labelled Pd
0
-microspheres were washed with MeOH (3 x 1 mL) 
and water (3 x 1 mL), and a ninhydrin test carried out. If the test was positive, the 
procedure was repeated.  
 
4.3.1.4    Preparation of Pd
0
-microspheres labelled with Cy5.5 
Cy5.5-(CH2)5COOH (2 mg, 3.4 µmol) and N-hydroxysuccinimide (0.6 mg, 5.2 
µmol) were dissolved in DMF (1 mL), DIC (2 µL, 19 µmol) and DMAP (catalytic 
amounts) were added and the mixture was stirred overnight. The reaction mixture 
was added to the Fmoc deprotected Pd
0
-microspheres (0.5 mL) and stirred overnight. 
The beads were washed with DMF (3x 1 mL), MeOH (3x 1 mL) and water (3x 1 
mL).  
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4.3.2    Cellular Uptake Studies  
Cellular uptake of Pd
0
-microspheres was evaluated on HeLa cells by incubation of 
fluorescently-labelled Pd
0
-microspheres for 24 hours, with intracellular fluorescence 
investigated by confocal microscopy and flow cytometry. Texas Red-labelled Pd
0
-
microspheres were used for the confocal microscopy studies, while Cy5.5-labelled 
Pd
0
-microspheres were used for the flow cytometry analysis.  
 
4.3.2.1    Confocal microscopy study 
After incubation, cells were washed twice with PBS then the HeLa cells were fixed 
with 4% formaldehyde in PBS for 30 minutes. Nuclei and cellular membrane were 
stained using a 10 g/mL solution of HOECHST 33342 in media (5 min at 37°C) and 
a 1 nM of 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DilC 
18) in Hank’s Buffered Salt Solution (HBSS) (30 min), respectively.  
 
4.3.2.2    Flow Cytometry study  
After incubation, cells were washed twice with PBS, harvested with trypsin/EDTA 
and resuspended in 2% FCS in PBS buffer. The internalization of labelled-
microspheres was analyzed by flow cytometry of Cy5.5 signals detected under the 
780/60 band pass filter.  
 
4.3.2.3    Cytotoxicity of Pd
0
-microspheres  (MTT assay) 
Cytotoxicity tests were carried out on HeLa cell line. Cells were plated in a 96-well 
plate with a density of 5,000 cells/well and left to grow for 24 hours. Two 
concentrations of Pd
0
-microspheres were studied (0.25 L/100 L (C1, 1.53x10
9
 





added to the well and incubated with the cells for 24 hours. Each condition was 
carried out in triplicate, with cells growth monitored under a microscope.  
 
4.3.2.4    Counting and replating  
HeLa cells were diluted in RPMI-CM (1 mL) at a density of 40,000 cells/well, plated 
in a 12 well plate and grown for 24 hours. Pd
0
-microspheres (Texas red or Cy5.5 
labelled) in media were added to the well plates and incubated for another 36 hours. 
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The media was removed, the cells were washed with PBS (10 mM) and then 
detached with trypsin (2.5% in EDTA) for 5 min at 37
o
C .The cells were diluted with 
1 mL of media, counted by phase contrast microscopy using trypan blue, and then 
replated for 1 h. The number of cells in the suspension after 1 hour was quantified by 
phase contrast microscopy using trypan blue (in triplicate).  
 
4.3.3    Pd
0
-mediated Allyl-carbamate Cleavage in Living Cells 











Bis-allyloxycarbonyl-protected Rhodamine 110, 28, was synthesised from rhodamine 
110 (27), as previously described.
150
 The resulting product (Rf = 0.35 using 
hexane/ethyl acetate (2:1)) was isolated as a white solid (150 mg, 30%). M.p.: 178- 
180°C; 
1
H NMR (250 MHz, DMSO-d6) 2 (ppm) 10.08 (s, 2H), 8.03 (d, J = 7.5 Hz, 
1H), 7.79 (td, J = 7.4, 1.2 Hz, 1H), 7.71 (td, J = 7.4, 1.0 Hz, 1H), 7.56 (d, J = 2.0 Hz, 
2H), 7.27 (d, J = 7.5 Hz, 1H), 7.14 (dd, J = 8.7, 2.1 Hz, 2H), 6.72 (d, J = 8.7 Hz, 2H), 
5.98 (m, 2H), 5.36 (ddt, J = 17.2, 1.7, 1.6 Hz, 2H), 5.22 (ddt, J = 10.5, 1.6, 1.4 Hz, 
2H), 4.62 (dt, J = 5.5, 1.4 Hz, 4H). 
13
C NMR (125 MHz, DMSO-d6) 2 (ppm) 168.6, 
153.1, 152.5, 150.9, 141.4, 135.7, 132.9, 130.1, 128.5, 125.7, 124.7, 123.9, 117.8, 
114.4, 112.4, 105.1, 81.9, 64.9. IR (thin film) v (cm-1) = 3306, 2926, 1750, 1614, 
1552, 1526, 1424, 1351, 1285, 1219, 1108, 1058, 992, 871, 763. HPLC 
(GE10CM5A, λ=254) 100% pure, retention time 3.9. LRMS (ES+) Calc. for 
C22H14F3O7S [M+ H]
+
 = 498.14, found: [M+H]
+









25 L of a 20 mM solution of compound 28 in DMSO (0.5 µmol) was diluted with 
1.0 mL of water and was used as a negative control (Figure 3.6A). 
 
Allylcarbamate deprotection of compound 28 in solution 
25 L of a 20 mM solution of compound 28 in DMSO (0.5 µmol) was diluted with 
975 µL of water to give a final concentration of 0.5 mM. Un-labelled Pd0-
microspheres (8.0 mol, 100 L) were added and the reaction shaken at 300 rpm for 
24 hour at 37°C (Figure 3.6B). Reaction progress was monitored by TLC.  
 
Allylcarbamate deprotection of compound 28 in solution with thiophenol  
25 L of a 20 mM solution of compound 28 in DMSO (0.5 µmol) was diluted with 
975 µL of water to give a final concentration of 0.5 mM., followed by 35 L of a 
thiophenol solution (100 mM in DMSO). Un-labelled Pd
0
-microspheres (8.0 mol, 
100 L) were added and the reaction shaken at 300 rpm for 24 hour at 37°C (Figure 
3.6C). Reaction progress was monitored by TLC. 
 
4.3.3.3    Alloc deprotection - flow cytometry 
HeLa cells were plated in RPMI-CM (1 mL) in 12-well microplates with a density of 
40,000 cells/well and cells were grown for 24 hours. Thereafter Cy5.5-labelled Pd
0
-
microspheres (1 L/1 mL RPMI-CM, 6.11 x 10
8
 beads/mL) (0.17 µM Pd0) in 1000 
L media were added and incubated for another 24 hour. The media of the cells was 
removed and cells washed with PBS (3 x) to eliminate extracellular Pd
0
-
microspheres. Protected Rhodamine 110, 28 (20 mM in DMSO) was added to a final 
concentration of 30M and incubated at 37°C and 5% CO2 for 24 hours. After the 
incubation time, cells were washed twice with PBS, harvested with trypsin/EDTA 




4.3.3.4    Alloc deprotection - confocal microscopy 
For the confocal microscopy study, HeLa cells were cultured on sterilised cover slips 
(24 mm) coated with 0.01% poly-lysine in water for 5 minutes at room temperature. 
The cover slips were washed with PBS (3x). The cover slips were placed in 6-well 
plates and seeded with 90,000 cells/well in 1600 L RPMI-CM and incubated 
overnight. Texas Red-labelled Pd
0
-microspheres (1 L/1 mL RPMI-CM, 6.11 x 10
8
 
beads/mL) (0.17 µM Pd0) were added to the cells and incubated for another 24 hours. 
The media of the cells was removed and extracellular Pd
0
-microspheres removed by 
intensive washing with PBS (3x). Protected Rhodamine 110 (28) (20 mM in DMSO) 
was added to a final concentration of 30 M and incubated at 37°C and 5% CO2 for 
24 hours. After incubation, cells were washed twice with PBS and the cells were 
fixed with 4% formaldehyde in PBS for 15 minutes. Nuclei were stained by 
incubation with a 10 g/mL solution of HOECHST 33342 in media for 5 minutes at 
37°C, then washed with PBS, and the membrane stained by incubation with 1 nM of 
1,1-dioctadecyl-3,3,3,3- tetramethylindocarbocyanine perchlorate (DilC 18) in 
Hank’s Buffered Salt Solution (HBSS) for 30 minutes at room temperature. Cells 
were imaged using a Leica SP5 Confocal. Microscope lasers setting were: excitation 
laser lines at 488 nm, 543 nm, 595 and 633 nm with emission filters of 385-470nm 
for HOECHST 33342 (nuclei stain), 505-530nm for Rhodamine 110 (27), 670-
690nm for DilC 18 (membrane stain), 595-615nm for Texas Red (Pd
0
-microspheres).     
 
 
4.3.3.5   In vitro study 
Conversion studies of allylcarbamate cleavage were carried out in PBS, DMF, RPMI 
media and cell extracts, with the reaction carried out at 37°C for 30 hours. 
Fluorescence due to Rhodamine 110 formation was measured on a SPEX Fluoromax 




Figure 4.1 Standard curve of Rhodamine 110 (27) on six data-points at emission 
520nm. The excitation and emission slits were 2nm. 
 
 
4.3.4    Making C–C Bonds within Cells 
4.3.4.1 Synthesis of 6’-methyl-3’-(trifluoromethanesulfonyl)fluorescein (29)139 
 
 
3´-(trifluoromethanesulfonyl)fluorescein, 2, (0.4 mmol, 186 mg), methyl iodide (2.0 
mmol, 125L) and potassium carbonate (0.6 mmol, 83 mg) were stirred in dry DMF 
(10 mL) and microwave-irradiated at 150°C for 60 minutes. The reaction mixture 
was partitioned between EtOAc (120 mL) and 1 M HCl (80 mL), the aqueous layer 
was extracted with EtOAc (2 x 30 mL), and the combined organics dried (MgSO4) 
and reduced in vacuo. Purification of the residue via column chromatography on 
silica gel (2:1 Hexane:EtOAc, Rf: 0.4) afforded compound 29 as a colourless solid 
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H NMR (500 MHz, DMSO-d6) δ = 
8.07 (1H, d, J 7.1 Hz, ArH), 7.87-7.74 (2H, m, ArH), 7.72 (1H, d, J 2.5 Hz, ArH), 
7.39 (1H, d, J 7.3 Hz, ArH), 7.26 (1H, dd, J 8.8 Hz, 2.6 Hz, ArH), 7.04 (1H, d, J 8.9 
Hz, ArH), 6.78 (1H, s, ArH), 6.66 (2H, s, ArH), 3.75 (CH3); 
13
C NMR (75 MHz, 
DMSO-d6) δ 170.69 (C=O), 163.23 (C), 153.97 (C), 153.32 (C), 153.18 (C), 151.45 
(C), 136.90 (CH), 131.54 (CH x2), 129.98 (CH), 127.41 (C), 126.14 (CH), 125.07 
(CH), 121.84 (C), 118.31 (CH), 113.55 (CH), 111.72 (CH), 111.68 (C), 102.05 (CH), 
80.83 (C), 56.21 (CH3O); MS (ES
+
): m/z 479.0 [100, (M+H)
+
]; HRMS calcd for 
C22H14F3O7S [M+ H]
+
 = 478.0334, found: 478.0356 ; RP HPLC tR = 3.7 minutes 
(100% purity, ELSD).   
 





4-Aminophenylboronic acid pinacol ester, 31, (0.5 mmol, 110 mg) and (4-bromo 
butyl)triphenylphosphonium bromide, 30, (0.6 mmol, 287 mg) were dissolved in 10 
ml DCM. Subsequently, triethylamine (2.0 mmol, 278  µL) was added and the 
reaction was microwave-irradiated for 60 min at 60°C. The solvent was removed 
under reduced pressure to give a pink solid which was purified by column 
chromatography on silica gel (DCM/MeOH 98:2) to yield 32 as a colourless solid 






H NMR (500 MHz, DMSO-d6) δ = 
7.90-7.72(15H, m, PPhH), 7.47 (2H, d J=8.4 Hz, ArH), 6.54 (2H, d, J=8.4 Hz, ArH), 
3.66-3.22 (4H, m, CH), 2.06-2.03 (2H, m, CH), 1.89-1.77 (4H, m, CH), 1.30 (12H, s, 
CH3); 
13
C NMR (75 MHz, CH3OD) δ 165.69 (C=O), 162.22 (C), 152.92 (C), 151.12 
(C), 150.18 (C), 149.49 (C), 136.90 (CH), 131.54 (CH x2), 129.98 (CH), 127.41 (C), 
126.14 (CH), 125.07 (CH), 121.84 (C), 118.31 (CH), 113.55 (CH), 111.72 (CH), 
111.68 (C), 102.05 (CH), 101.83 (C), 56.3.13 (4CH3); MS (ES
+




]; HRMS calcd for C34H40BNO2 [M+ H]
+
: 537.2884, found: 537.2964; RP 
HPLC tR = 3.9 minutes (100% purity, ELSD). 
 
4.3.4.3    Synthesis of (4-[4’-(3’’-methoxyfluoran-6’’-




Compound 29 (0.4 mmol, 192 mg), compound 32 (0.5 mmol, 268 mg), palladium 
acetate (4.5 mg, 0.02 mmol) and triphenylphosphine (21 mg, 0.08 mmol) were added 
in a microwave vial followed of 10 mL of degassed dioxane. Subsequently, 
potassium carbonate (83 mg, 0.6 mmol) in water (1 mL) was added and the resulting 
mixture was stirred and microwave irradiated at 120°C for 30 min. The reaction 
mixture was partitioned between EtOAc (50 mL) and 1 M HCl (40 mL), the aqueous 
layer was extracted with EtOAc (2 x 20mL) and the combined organic phases were 
dried over MgSO4, and filtered off. The solvent was removed under reduced pressure 
to give a dark red solid which was purified by column chromatography on silica gel 





H NMR (400 MHz, CH3OD) δ= 8.07-6.74 (29H, m, ArH), 3.99-3.86 (5H, m, 
OCH3, CH2) 3.40-3.30 (2H, m, CH2), 2.03-1.96 (2H, m, CH2), 1.75-1.72 (2H, m, 
CH2);
 13
C NMR (75 MHz, CH3OD) δ 164.45 (C=O), 163.23 (C), 153.97 (C), 153.22 
(C), 152.18 (C), 150.45 (C), 136.90 (CH), 131.54 (CH x2), 128.96 (CH), 127.41 (C), 
125.15 (CH), 124.04 (CH), 120.80 (C), 117.31 (CH), 114.55 (CH), 111.72 (CH), 
111.68 (C), 102.05 (CH), 80.83 (C), 56.21 (CH3); MS (ES
+
): m/z 737.3 [100, 
(M+H)
+
]; HRMS calcd for C49H40NO4P [M+ H]
+
: 738.2762, found: 738.2768; RP 
HPLC tR = 3.8 minutes (100% purity, ELSD); Φ: 0.32; Ex/Em: 488/540 nm.  
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6’-methyl-3’-(trifluoromethanesulfonyl)fluorescein, 29, (0.4 mmol, 186 mg) and 
potassium carbonate (0.6 mmol, 83 mg) were stirred in water (10 ml) and 
microwave-irradiated at 150°C for 1 hour The reaction mixture was partitioned 
between EtOAc (120 mL) and 1 M HCl (80 mL), the aqueous layer was extracted 
with EtOAc (2 x 30 mL), and the combined organics dried (MgSO4) and reduced in 
vacuo. Purification of the residue via column chromatography on silica gel (1:1 
Hexane:EtOAc, Rf: 0.2) afforded compound 34 as an orange solid (131mg, 0.38 




H NMR (500 MHz, CH3OD) δ = 8.29 (1H, d, J 7.1 
Hz, ArH), 7.85-7.78 (2H, m, ArH), 7.42 (1H, d, J 2.5 Hz, ArH), 7.01 (1H, d, J 7.3 
Hz, ArH), 7.00 (1H, dd, J 8.8 Hz, 2.6 Hz, ArH), 6.75 (1H, d, J 8.9 Hz, ArH), 6.70 
(1H, s, ArH), 6.68 (2H, s, ArH), 3.61 (CH3); 
13
C NMR (125.8 MHz, CH3OD) δ 
188.15 (C=O), 166.23 (C), 166.98 (C), 160.87 (C), 154.01 (C), 153.27 (C), 135.01 
(CH), 134.50 (CH x2), 132.78 (CH), 132.49 (C), 131.97 (CH), 131.66 (CH), 131.45 
(C), 131.23 (CH), 122.71 (CH), 121.56 (CH), 119.29 (C), 106.56 (CH), 80.83 (C), 
52.99 (CH3O); MS (ES
+
): m/z 347.0 [100, (M+H)
+
]; HRMS calcd for C21H14O5 [M+ 
H]
+
:; RP HPLC tR = 4.2 minutes (100% purity, ELSD); Φ: 0.26; Ex/Em: 488/518nm. 
 
4.3.4.5   Hydrolytically stable compound 29 
1 mM compound 29 was stirred in PBS (1 mL) at 37
o
C for 48 hours. The solution 





4.3.4.6   Suzuki-Miyaura cross-coupling in HeLa cells - flow cytometry 
HeLa cells were plated in 12 well plate (40,000 cells/well) and incubated at 37
o
C for 
24 hours. The media was removed and replaced with 1000 L media containing 
Cy5.5-labelled Pd
0
-microspheres (1 L/1 mL RPMI-CM, 6.11 x 10
8
 beads/mL) (0.17 
µM Pd0))  and incubated at 37oC for 24 hours. The media of the cells was removed 
and any excess extracellular Pd
0
-microsperes eliminated by subsequent washing with 
PBS (x3). Compounds 29 and 32 (20 mM) in DMSO were diluted with fresh media 
to give a final concentration of 20 M of each reagent, added to the cells and 
incubated at 37
o
C for 48 hours. After incubation, cells were washed twice with PBS, 
harvested with trypsin/EDTA and resuspended in 2% FCS in PBS buffer. The 
intracellular presence of Cy5.5-labelled Pd
0
-microspheres and fluorescent compound 
33 were analyzed by flow cytometry under different band pass emission filters 
(780/60 and 576/26, respectively).  
 
4.3.4.7   Experiments analysed by confocal microscopy 
For the confocal microscopy study, HeLa cells were cultured on sterilised cover slips 
(24 mm) coated with 0.01% poly-lysine in water for 5 minutes at room temperature. 
The cover slips were washed with PBS (3x). The cover slips were placed in 6-well 
plates and seeded with 90,000 cells/well in 1600 L RPMI-CM and incubated 
overnight. Texas Red-labelled Pd
0
-microspheres (1 L/1 mL RPMI-CM, 6.11 x 10
8
 
beads/mL) (0.17 µM Pd0) were added to the cells and incubated for another 24 hours. 
The media of the cells was removed and extracellular Pd
0
-microspheres removed by 
intensive washing with PBS (3x). Compounds 29 and 32 (20 mM in DMSO) were 
diluted in fresh media to a final concentration of 20 M, added to the cells and 
incubated at 37°C and 5% CO2 for 48 hours. After the incubation time, the media 
was removed and mitochondria were stained by addition of 50 nM of MitoTracker
®
 
Deep Red in media at 37°C for 30 minutes. Subsequently, cells were washed twice 
with PBS and the cells were fixed with 4% formaldehyde in PBS for 30 min. Nuclei 
were stained by incubation with a 10 g/mL solution of HOECHST 33342 in media 
for 5 minutes at 37°C. Cells were imaged using a Leica SP5 Confocal. Microscope 
lasers setting were: excitation laser lines at 488nm, 543nm, 595 and 633nm with 
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emission filters of 385-470nm for HOECHST 33342 (nuclei stain), 540-560nm for 
compound 33, 650-670nm for MitoTracker
®
 Deep Red (mitochondria stain), 595-




4.3.4.8   Standard curve 
Using the same way of making standard curve for rhodamine 110, standard curve of 





Figure 4.2 Standard curves of compound 33 at emission 520nm (emission at 488nm). 
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3   (3-(2,3-
dihydrobenzofuran-6-
yl)-6-oxo-6H-xanthen-
9-yl)benzoic acid 
 
7 
2-(3-(1H-indol-6-yl)-
6-oxo-6H-xanthen-9-
yl)benzoic acid 
 
8 
2-(3-(1-methyl-1H-
indol-5-yl)-6-oxo-6H-
xanthen-9-yl)benzoate 
 
9 
2-(3-(furan-2-yl)-6-
oxo-6H-xanthen-9-
yl)benzoic acid 
 
10 
2-(3-oxo-6-(thiophen-
2-yl)-3H-xanthen-9-
yl)benzoic acid 
 
11 
2-(3-(benzofuran-2-
yl)-6-oxo-6H-xanthen-
9-yl)benzoic acid 
 
12 
 143 
of 2-(3-
(benzo[b]thiophen-2-
yl)-6-oxo-6H-xanthen-
9-yl)benzoic acid 
 
13 
2-(3-oxo-6-phenyl-3H-
xanthen-9-yl)benzoic 
acid 
 
14 
2-(3-oxo-6-(pyren-2-
yl)-3H-xanthen-9-
yl)benzoic acid 
 
15 
2-(3-(4-
(dimethylamino)pheny
l)-6-oxo-6H-xanthen-
9-yl)benzoic acid 
 
16 
2-(3-(4-
methoxyphenyl)-6-
oxo-6H-xanthen-9-
yl)benzoic acid 
 
17 
2-(3-(3-
methoxyphenyl)-6-
oxo-6H-xanthen-9-
yl)benzoic acid 
 
18 
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2-(3-(4-
carboxyphenyl)-6-oxo-
6H-xanthen-9-
yl)benzoic acid 
 
19 
2-(3-(3-
carboxyphenyl)-6-oxo-
6H-xanthen-9-
yl)benzoic acid 
OO
COOH
COOH
 
20 
of 2-(3-oxo-6-(4-
(trifluoromethyl)pheny
l)-3H-xanthen-9-
yl)benzoic acid 
 
21 
2-(3-oxo-6-p-tolyl-3H-
xanthen-9-yl)benzoic 
acid 
 
22 
2-(3-(4-nitrophenyl)-6-
oxo-6H-xanthen-9-
yl)benzoic acid 
 
23 
2-(3-(4-cyanophenyl)-
6-oxo-6H-xanthen-9-
yl)benzoic acid 
 
24 
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of 2-(3-(4-
chlorophenyl)-6-oxo-
6H-xanthen-9-
yl)benzoic acid 
 
25 
2-(3-(4-aminophenyl)-
6-oxo-6H-xanthen-9-
yl)benzoic acid 
 
26 
bis-allyloxycarbonyl-
protected rhodamine 
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28 
6’-methyl-3’-
(trifluoromethanesulfo
nyl) 
fluorescein 
 
29 
(4-[4’-
(pinacolatoboron)phen
ylamino] 
butyl)triphenyl  
phosphonium bromide 
 
 
32 
 146 
(4-[4’-(3’’-
methoxyfluoran-6’’-
yl)phenylamino]butyl) 
triphenyl phosphonium 
bromide 
 
33 
6’-methylfluorescein 
 
34 
